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"Rather than approaching access and benefit sharing as a problem to be
overcome, it should be seen as an opportunity to work with partners in
countries providing access to genetic resources, to increase the impact of the
research being undertaken and, ultimately, to exercise the principles of equity
and fairness." - Braulio Ferreira de Souza Dias1
I. INTRODUCTION
International research collaborations have been the engines of some of the
most important advances in human health and nutrition over the last century. The
Green Revolution, built on networks of scientists and resources drawn from the
world's wealthiest and poorest countries, averted critical food shortages that
faced the growing world population in the 1950s and 1960s.2 The most promising
vaccine candidates for devastating infectious diseases like Ebola and HIV have
resulted from partnerships of financial resources, governments, and scientists
from the Democratic Republic of Congo, Guinea, Liberia, Sierra Leone, South
Africa, and Thailand. Orchestrated technology transfer and research capacity
building in low- and middle-income countries have delivered advances in the
ability of low-resource countries to manufacture medicines and vaccines.
Scientists have worked together across borders as threats posed by infectious
disease, malnutrition, and environmental degradation necessitate partnerships
that match the technology and resources in wealthy countries with the knowledge
and biodiversity abundant in many poorer ones.3 These collaborations have
rendered multiple positive effects-not only in the form of solutions to the
problems initially considered, but also in the form of increased local capacity as
laboratories are built, knowledge is shared, and technology is transferred.
1Braulio Ferreira de Souza Dias, Foreword to RESEARCH AND DEVELOPMENT ON GENETIC RESOURCES:
PUBLIC DOMAIN APPROACHES IN IMPLEMENTING THE NAGOYA PROTOCOL, at xviii (Evanson Chege
Kamau et al. eds., 2015).
2 Raj Patel, The Long Green Revolution, 40 J. PEASANT STUD. 1, 5-6 (2013).
3 See generally The Future of Food and Agriculture, FOOD & AGRIC. ORG. UNITED NATIONS (2017),




There were, of course, negative effects as well. Not all of these research
activities were collaborative, and many were exploitative. Researchers based in
Europe and North America often transferred materials from low- and middle-
income countries to laboratories in richer ones, sharing little of the resulting
knowledge, technology, or products. It is this history that has made the
environment for current life-sciences research collaborations so legally complex.
Indeed, much technological progress now occurs in a world of growing
divisions between developing and developing countries.4 Developments in
international law over the last twenty-five years have worked to ensure that not
only are the governments of the world's most biodiverse countries consulted
about research activities, but also that the benefits from research flow to them
and their populations. The promise of new breakthroughs in medicine and
agriculture are therefore wedded to the international law of biodiversity, as well
as imbued with ethical obligations to ensure that speculative research is not
favored over using existing resources to meet the needs of humans living today,
billions of whom live in poverty and deprivation. This Article endeavors to
address that complex juxtaposition of scientific possibility and basic human
needs.
As life sciences technologies have advanced, so too has the potential for
these international collaborations to lead to breakthrough medicines, enhance
food security, and protect ecological systems. The linchpin of this progress is the
development of high throughput genetic sequencing technologies. Researchers
are now able to generate and compare large stretches of DNA - 1 million bases
or more - from different sources quickly and inexpensively. Such comparisons
can yield massive amounts of information about the role of inheritance in
susceptibility to infection and illness as well as responses to environmental
influences. In addition, the ability to sequence genomes more quickly and
inexpensively creates enormous potential for new diagnostics and therapies.
5
This is true not only for sequencing the human genome, but also for sequencing
the genomes of simple and complex organisms that comprise the entire human
environment.
This Article will first provide examples of where international collaborations
have led to advances in medical and agricultural benefits for populations in both
rich and poor countries. It will then describe how new life sciences research
collaborations, primarily using genetic sequencing technology, may detect
potential human pathogens, characterize microbial life, and catalogue the unique
genetic information in all wildlife species. It will situate these biogenomic
projects in the context of the international access and benefit sharing law, derived
from several sources, but most importantly the 1993 Convention on Biological
Diversity (CBD). Finally, this Article will analyze four of these new international
collaborations to demonstrate that the common tensions that arise between
4 See, e.g., SAM HALABI, INTELLECTUAL PROPERTY AND THE NEW INTERNATIONAL ECONOMIC ORDER
43-45 (2018) [hereinafter Halabi, Intellectual Property].
See DNA Sequencing Fact Sheet, NAT'L HUM. GENOME RES. INST. (Dec. 18, 2015),
https://www.genome.gov/10001 177/dna-sequencing-fact-sheet/.
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generating scientific and other benefits through exploiting new research
possibilities, and meeting the food and medical needs of the world's population
today are often reconcilable.
Part I of this Article outlines the law and ethics of life sciences research
partnerships as they unfolded over the course of the twentieth century. Part II
analyzes how advances in genetic sequencing technology may accelerate the
pace and impact of new life sciences research collaborations. Part II also
examines the development of international law over the course of those
technological advances, and how the law now requires or shapes partnerships to
benefit all participants and to be mindful of constituencies who may or may not
benefit. Part III examines four major collaborations, using these case studies to
show how the international law of biodiversity is shaping their objectives and
channeling their benefits and also addressing persistent ethical questions about
the use and distribution of scarce resources. Part IV sets out the conclusions.
A. Agriculture and Nutrition
After World War II, virtually the entire globe, but especially the least
developed regions of it, faced food shortages, growing populations, and regular
famine.6 In response, scientists from India, Mexico, the Philippines, and the
United States, in partnership with major international organizations and
foundations, created a global biological commons in plant genetic resources,
implemented through a system of cross-country research experiments creating
international nurseries, breeding hubs, and the free sharing of seeds and related
genetic information.7 The high-yield varieties of cereal grains resulting from
these collaborations were accompanied by orchestrated technology transfers
from wealthier countries to poorer ones. Farmers were able to adopt the new high
yield varieties quickly, and food production was able to keep up with local
population growth. Now known as the Green Revolution, the effort boosted
average caloric intake in emerging regions as food prices declined, leading to
better indicators of health and a longer life expectancy. 8
The Green Revolution also created mechanisms to sustain the scientific
collaborations that explained its success. Initially, a group of seventeen member
countries, international organizations, and foundations comprised the
Consultative Group for International Agricultural Research (CGIAR).9 Seven
new members were added in the 1970s that were primarily concerned with core
breeding programs, including for livestock.' 0 Then, five more members were
See William B. Dickinson Jr., World Food Shortages, in 2 EDITORIAL RESEARCH REPORTS 547
(1965), http://library.cqpress.com/cqresearcher/cqresrre 1965072800.
7 See Derek Byerlee & H.J. Dubin, Crop Improvement in the CGIAR as a Global Success Story of Open
Access and International Collaboration, 4 INT'L J. COMMONS 452, 455-56 (2010).
' See R. E. Evenson & D. Gollin, Assessing the Impact of the Green Revolution, 1960 to 2000, 300 SCI.
758, 761 (2003).




added in the 1980s with a strong focus on natural resources management and
policy research." Each member "relied on similar principles of networks and
open sourcing," such as databases for natural resources management research,
and "[b]y 2007, the CGIAR had grown to include 64 members," all with a
continuing commitment to the research and development of genetic resources for
food, especially for the world's poorest populations. 12 CGIAR research is carried
out through international agricultural research centers (JARCs) located
overwhelmingly in developing countries. The IARCs conduct research to
improve and create new germplasm from which to develop seeds.' 3
It is estimated that "without the CGIAR and national program crop
germplasm improvement efforts, food production in developing countries would
have been almost 20% lower."' 14 To compensate, another 20-25 million hectares
of land under cultivation would have been necessary worldwide.' 5 As Pingali
notes, "[w]orld food and feed prices would have been 35-65% higher, and
average caloric availability would have declined by 11-13%. ' '16 Overall, these
efforts benefited virtually all consumers in the world, with disproportionate
benefit being passed onto poor populations, who spend a greater share of their
income on food.
17
The benefits of the Green Revolution for local communities appear to
significantly outweigh the costs. The Green Revolution had the effect of
introducing or intensifying the use of fertilizer, insecticide, pesticide, and
fungicide agents that have imposed a burden on local water and ecosystems.' 8
Because large-scale farmers adopted Green Revolution more quickly, it had the
effect of pressuring the market share and sustainability of smaller farms.' 9 It also
laid the groundwork for the increasing assertion of intellectual property claims
over agricultural inputs, as seeds and pesticides available from the public domain
decreased.z Yet its net effect has been profoundly positive. As researchers at
Oregon State University concluded:
The Green Revolution led to sizable increases in returns to land,
and hence raised farmers' incomes. Moreover, with greater
income to spend, new needs for farm inputs, and milling and
marketing services, farm families led a general increase in
See id.; FRtDtRIC GAGNON-LEBRUN, INTERNATIONAL ENERGY TECHNOLOGY COLLABORATION AND
CLIMATE CHANGE MITIGATION (2004).
12 Byerlee & Dubin, supra note 7, at 457.
13 See Evenson & Gollin, supra note 8, at 759.
'4 Prabhu Pingali, Green Revolution: Impacts, Limits, and the Path Ahead, 109 PROC. NAT'L ACAD. SCI.




"8 Saidur Rahman, Green Revolution in India: Environmental Degradation and Impact on Livestock, 12
ASIAN J. WATER, ENV'T. AND POLLUTION 75 (2015).
'9 See Green Revolution: Curse or Blessing?, INT'L FOOD POL'Y RES. INST. 3 (2002),
https://oregonstate.edu/instruct/css/330/three/Green.pdf [hereinafter IFPRI Report].
20 Halabi, Intellectual Property, supra note 4, at 225 (noting the increase in wealthy states' intellectual
property claims throughout 1980s and 1990s).
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demand for goods and services. This stimulated the rural
nonfarm economy, which in turn grew and generated
significant new income and employment of its own. Real per
capita incomes almost doubled in Asia between 1970 and 1995,
and poverty declined from nearly three out of every five Asians
in 1975 to less than one in three by 1995.The absolute number
of poor people fell from 1.15 billion in 1975 to 825 million in
1995 despite a 60 percent increase in population. In India, the
percentage of the rural population living below the poverty line
fluctuated between 50 and 65 percent before the mid-1 960s but
then declined steadily to about one-third of the rural population
by 1993. Research studies show that much of this steady
decline in poverty is attributable to agricultural growth and
associated declines in food prices. The Green Revolution also
contributed to better nutrition by raising incomes and reducing
prices, which permitted people to consume more calories and a
more diversified diet.2 '
B. Human Health and Medicine
The greatest non-military threats to human life (and some military ones) are
posed by infectious diseases. Since 1981, HIV/AIDS has afflicted approximately
70 million, killing half of them.22 Influenza killed 3% of the world's population
in two years (1918-19) and continues to kill hundreds of thousands annually.23
In the last 200 years, tuberculosis alone has killed over one billion people.
24
International scientific collaborations have resulted in medicines, vaccines, and
preventative technologies that have drastically reduced the burdens imposed by
these diseases.
1. HIV/AIDS
Scientists discovered the virus that caused AIDS in 1983, largely because of
increasing reports of rare types of pneumonia, cancer, and other illnesses in
specific populations like gay men, Haitians returning from the Democratic
21 IFPRI Report, supra note 19, at 3.
22 Carlos del Rio, The Global HIV Epidemic: What the Pathologist Needs to Know, 34 SEMINARS
DIAGNOSTIC PATHOLOGY 314-17 (July 2017),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531065/pdf/nihms878509.pdf ("[B]y 1981 when the
first case of AIDS were identified... HIV had been circulating in the US for a decade. Since then, more
than 70 million people have been infected with HIV and about 35 million have died as a result. The
World Health Organization (WHO) estimates that at the end of 2015, 36.7 million [34.0-39.8 million]
people were living with HIV and an estimated 0.8% of adults aged 15 - 49 years are infected with
HIV").
23 See Richard Gunderman, Ten Myths About the 1918 Flu Pandemic, SMITHSONIAN MAG. (Jan. 12,
2018), https://www.nsmithsonianmag.com/history/ten-myths-about-1918-flu-pandemic- 180967810/;
Jennifer Latson, What Made the Spanish Flu So Deadly?, TIME (Mar. 11, 2015),
http://time.com/3731745/spanish-flu-history.
24 See Tom Paulson, Epidemiology: A Mortal Foe, 502 NATURE S2, S2 (2013).
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Republic of Congo, and intravenous drug users.25 By the end of 1986, "85
countries had reported 38,401 cases of AIDS to the World Health
Organization." 26 By the early 1990s, the population of people living with
HIV/AIDS exploded in sub-Saharan Africa, quickly comprising the large
majority of the HIV/AIDS afflicted population worldwide.27 By 2001,
approximately twenty million people had died from AIDS, and another forty
million people were infected and/or dying. Sub-Saharan Africa accounted for
two-thirds of the people living with HI/AIDS, despite holding a relatively small
percentage of the global population.28
International scientific partnerships were crucial to the development of
antiretroviral treatments that have drastically reduced mortality from the disease
and have underpinned efforts to develop a vaccine. 29 The most promising
candidate, RV144, resulted from international scientific collaborations
stretching across the globe including major clinical trial sites in Thailand and
South Africa.30 A clinical trial of RV144 involved 26,658 participants in eastern
Thailand.3' Several factors have been noted as playing a critical role to the
successful implementation of these trials. Namely, active inclusion of the local
communities in the trial and performing trial activities within Thailand's existing
healthcare system while also strengthening Thai healthcare infrastructure and
capacity. Both the partial efficacy reported in the RV144 trial and the positive
results of the subsequent immune correlates analysis suggest an effective HIV
vaccine is within reach.32
The migration of H1V/AIDS research from richer to poorer countries,
especially clinical trials, has resulted in large scale transfer of medical
technology and knowledge to those countries. While there have been concerns
25 James W. Curran and Harold W. Jaffe, AIDS: The Early Years and the CDC's Response, 60 CENTER
FOR DISEASE CONTROL & PREVENTION 64, 64-69 (201 1); Robert C. Gallo & Luc Montagnier, The
Discovery ofHIV as the Cause of AIDS, 349 NEw ENG. J. MED. 2283, 2284 (2003).26 History of HIV and AIDS Overview, AVERT, https://www.avert.org/professionals/history-hiv-
aids/overview#footnote35 (last updated Oct. 10, 2019).27 JONATHAN MANN AND DANIEL TARANTOLA, AIDS IN THE WORLD II: GLOBAL DIMENSIONS, SOCIAL
ROOTS, AND RESPONSES 11 (1996).
28 The Global HIV/AIDS Epidemic, KAISER FAM. FOUND. (Sept. 9, 2019), https://www.kff.org/global-
health-policy/fact-sheet/the-global-hivaids-epidemic/,
29 See, e.g., ADVANCE, INT'L AIDS VACCINE INITIATIVE, https://www.iavi.org/our-work/clinical-
epidemiology-research/advance (last visited Nov. 13, 2019).
31 See generally Paul M. Sharp & Beatrice H. Hahn, The Evolution of HIV-1 and the Origin ofAIDS,
365 PHIL. TRANSACTIONS ROYAL SoC'Y B: BIOLOGICAL SCI. 2487, 2499-90 (2010) (outlining the
origins of HIV); see also Samuel Broder, The Development ofAntiretroviral Therapy and Its Impact on
the HIV-1/AIDSPandemic, 85 ANTIVIRAL RES. 1, 1 (2010) (unpublished manuscript),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2815149/pdf/nihmsl 53574.pdf (discussing the
development of antiretroviral therapy).
" Tracey A. Day & James G. Kublin, Lessons Learnedfrom HIV Vaccine Clinical Efficacy Trials, 11
CuRRENT HIV RES. 1, 10 (2013) (unpublished manuscript),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000156/pdf/nihms538919.pdf.
32See Ryan Lenora Brown & Lenny Bernstein, Major HIV Vaccine Trial in South Africa Stokes Hope,




THE YALE JOURNAL OF INTERNATIONAL LAW
raised about the standard of care adopted by researchers, the capacity-building
efforts of training more medical workers, funding more laboratories, and
educating more citizens have been well-documented.3 3
2. Influenza
Although there have been at least four influenza pandemics in the last
century, the Spanish influenza pandemic of 1918-19 was by far the worst, killing
approximately three percent of the world's population. 34 Influenza pandemics
threaten to recur because of the virus's capacity to reassort.35 Since the 1950s,
WHO's Global Influenza Surveillance and Response System (formerly Global
Influenza Surveillance Network) has served as one of the largest, continuously
operating international life sciences research collaborations in the world,
incorporating reference laboratories, researchers, and vaccine manufacturers.
36
This connection has generated seasonal and pandemic flu vaccines that have
saved millions of lives. 37 The system "monitor[s] the evolution of influenza
viruses and... provide[s] recommendations on which candidate vaccine viruses
should be included in seasonal and pandemic vaccines." 38 The system is
structured around six WHO collaborating centers located in Australia, China,
Japan, the U.K. and the U.S., four WHO essential resource laboratories, and 142
institutions recognized by WHO as national influenza centers (NICs) located in
112 countries. 39 NICs collect clinical specimens for the detection of influenza
viruses through national surveillance networks.40 This system collects influenza
samples from around the world, distributes them to collaborating centers, and
shares them, pursuant to material transfer agreements, with non-profit and for-
profit actors to develop vaccines and antivirals.
41
3 See, e.g., Lisa Judy Chin et al., HIV/AIDS Research Conducted in the Developing World and
Sponsored by the Developed World: Reporting of Research Ethics Committee Review in Two Countries,
6 J. EMPIRIcAL RES. HUM. RES. ETHICS 83 (2011); Amanda Silverio, HIV Research in Africa: A Series
of Paradoxes, FALL-WINTER 2002 STAN. J. INT'L REL. (2002) (discussing the ethical issues facing HIV
researchers).34 SAM F. HALABI & JOHN MONAHAN, Regulatory Capacity in Low- and Middle-Income Countries, in
FOOD AND DRUG REGULATION IN AN ERA OF GLOBALIZED MARKETS 64 (Sam F. Halabi ed., 2015);
Antoine Flahaut & Patrick Zylberman, Influenza Pandemics: Past, Present, and Future Challenges, 32
PUB. HEALTH REV. 319, 324-25 (2010).
"' Halabi and Monahan, supra note 34, at 64-65.
36 PIP Advisory Group, Global Influenza Surveillance and Response System, Self-Assessment of the
WHO Global Influenza Surveillance and Response System, WHO 1, 6 (2014),
http://www.who.int/influenza/pip/virus sharing/gisrs self assessment.pdf [hereinafter Self-Assessment].
" CDC Study: Flu Vaccine Saved 40, 000 Lives During 9 Year Period, CTRS. FOR DISEASE CONTROL &
PREVENTION (Mar. 30, 2015), https://www.cdc.gov/flu/spotights/2014-2015/flu-vaccine-saved-
lives.htm; see also Liz Szabo, CDC: Vaccines Save Hundreds of Thousands ofLives, USA TODAY (Apr.
24, 2014), https://www.usatoday.com/story/news/nation/2l4/04/24/cdc-vaccine-benefits/809 4 7 8 9 /.
" Self-Assessment, supra note 36.
31 CDC's World Health Organization (WHO) Collaborating Center for Surveillance, Epidemiology and
Control of Influenza, CDC (Nov. 24, 2015), https://www.cdc.gov/flu/weekly/who-collaboration.htm.
o Global Influenza Surveillance and Response System (GISRS), WHO (2015),
https://www.who.int/csr/disease/OPGISRSFINAL.pdf.
4 Operational Guidance on Sharing Seasonal Influenza viruses with WHO Collaborating Centers (CCs)
under the Global Influenza Surveillance and Response System (GISRS), WHO (2017) at 1, 4,




As with other international research collaborations, this sharing system is
accompanied by technology transfer agreements between the World Health
Organization, European and U.S. governments, and facilities in Brazil, Egypt,
India, Indonesia, Kazakhstan, Thailand, and Vietnam.4 2 There are now 13
influenza vaccine manufacturers in low-income countries and 4 in upper middle-
income countries with a capacity to produce 450 million doses.43
"[S]everal manufacturers, including some in developing countries, are
establishing adjuvant production and the use of these dose-sparing technologies
is anticipated to become more common within the next several years, doubling
their current pandemic capacity."44 India's pharmaceutical industry is now not
only producing influenza vaccines, but undertaking independent research and
development. By volume, India's drug industry is the world's fourth largest,
producing approximately 20% of active pharmaceutical ingredients.45
Traditionally, Indian firms spent little revenue on research and development and
most drug discovery research was supported by publicly funded research
institutes. In 2006, more than 175 firms had established research and
development centers and approximately 15 firms engaged in discovery research,
spending around 10% of revenue on research and development.46 "The industry's
total annual R&D investment is estimated at around US$170 million, which is
miniscule compared to that of 'big pharma', though this expenditure 'buys' more
R&D in India than in North America or Europe due to lower labour costs...,47
India, for example, is developing a vaccine against dengue, a mosquito-borne
disease that uniquely affects populations in poorer countries. 4 8
3. Tuberculosis
Tuberculosis (TB) is one of the world's deadliest diseases, with a
particularly profound impact on low- and middle-income countries. "More than
95 percent of TB deaths occur in low- and middle-income countries, and just
seven countries account for 64 percent of that total (in ranked order): India,
Indonesia, China, Philippines, Pakistan, Nigeria, and South Africa."49 TB can
42 Martin Friede, Snapshot of Current Influenza Vaccine Manufacturing Capacity Worldwide and
Summary of WHO-HHS Activities to Promote Technology Transfer, WHO (2011),
http://www.who.int/phi/Session1B Current ManufacturingCapacityWorldwide Friede.pdf.
" Kenneth A. McLean et al, The 2015 Global Production Capacity of Seasonal and Pandemic Influenza
Vaccine, 34 VACCINE 5412 (2016).
4Id.
4 Hans L~fgren, The Global Biopharna Industry and the Rise of Indian Drug Multinationals:
Implications for Australian Generics Policy, AUSTL. & N.Z. HEALTH POL'Y 4 (2007).46 Id. at5.47 Id.
41 Sathyamangalam Swaminathan & Navin Khanna, Dengue Vaccine Development: Global and Indian
scenarios, 84 INTL. J. INFECTIOUS DISEASES S80, S83-84 (2019).
41 Carol Dukes Hamilton, Outsmarting TB Using Research and Collaboration, R&E SEARCH FOR
EVIDENCE (Dec. 11, 2017), https://researchforevidence.fhi360.org/outsmarting-tb-using-research-
collaboration.
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quickly develop a resistance to treatments, even multiple-drug resistance.
50
Because resistance arises locally and contextually, the fight against TB requires
both international collaborations and dedicated resources to local variants.
51
Broadly, this dynamic in the disease, and the research required to address it,
have caused researchers in Europe and North America to build research
infrastructure in affected countries, while those countries target their more
limited resources on projects within national borders. 52 The Division of AIDS
(DAIDS), the National Institute of Allergy and Infectious Diseases (NIAID)
within the U.S., and the National Institutes of Health (NIH), have funded
infrastructure for routine technical and scientific input into several research
networks across the world.53 This infrastructure is adapted at the local level for
research into diagnostics, specific drug regimens for treating drug-susceptible
pulmonary TB; and preparation for recruitment into a high-profile, global study
of a new drug and shorter treatment regimen to treat multidrug-resistant TB.54
Bibliometric studies confirm the growing research and development
capacity in low- and middle-income countries through these partnerships. Of
published TB-related research papers, U.S.-based scientists produced the most
publications of any one country, with 18.4% of all references." Among the top
five publishing countries, three were high-burden TB developing countries:
India, China, and South Africa. Average year-on-year increases in publications
was 13.1% for the top five countries, nearly double that of the increase among
all countries.
56
Coordinating efforts by the World Health Organization and regional
bodies identify where international versus local resources may be most
effectively used.5 7 Rationalized research and innovation is one of the three pillars
of the World Health Organization's End TB Strategy, and the WHO has
developed the Global Action Framework for TB Research to foster high-quality
TB research for the period 2016 to 2025 at global and national levels.58
The net benefit to local research and disease treatment capacity has been
significant. TB technology transfer programs have re-purposed buildings,
50 Global Tuberculosis Report 2017, WHO (2017),
https://www.who.intltb/publications/global report/gtbr2Ol7_main text.pdf.
51 Two Arizona Leaders in Scientific Collaboration Partner to Advance Global TB Research, CRITICAL
PATH INSTITUTE (May 1, 2017), https://c-path.org/two-arizona-leaders-in-scientific-collaboration-
partner-to-advance-global-tb-research/.
52 James S. Molton et al, International Tuberculosis Research Collaborations Within Asia, 10 BMC RES
NOTES 1,4 (2017).
" Hamilton, supra note 49.
5 Id.
" Vaidehi Nafade et al., A Bibliometric Analysis of Tuberculosis Research, 2007-2016, 13 PLOS ONE 1,
3 (2018).
56 Id.
" WHO, Ministerial Declaration of 17 November 2017, WHO Doc. WHO/HTM/TB/2017.l (2017),
https://www.who.int/tb/featuresarchive/MoscowDeclaration toEndTB finalENGLISH.pdf?ua=l
" Molton, supra note 52, at 5.
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provided significant support for laboratory development, and supported travel
for local health workers to be trained in Europe and North America as training
programs are developed in country.59 Investment in TB research pays off
disproportionately given the costs in worker mortality and morbidity to say
nothing of the toll it takes on children in developing countries. The World Health
Organization argues that "investing in TB research today will offer significant
cost savings to health systems in the long run. The Copenhagen Consensus has
identified spending on TB as a 'best buy,' based on the calculation that reducing
deaths from TB would be worth US$43 for every dollar spent., 60
II. SEQUENCING THE WORLD: THE NEXT GENERATION OF
INTERNATIONAL RESEARCH COLLABORATIONS FOR HUMAN
HEALTH AND NUTRITION
The aforementioned research efforts in human health, agriculture, and
medicine required massive investments of capital, labor, and technology and
frequently responded to malnutrition and public health crises or emergencies
rather than investing in detection and prevention of food insecurity and disease.
Recent international collaborations aim to address the imbalance between
response and prevention, seeking to anticipate and address future challenges to
human health and security rather than responding to those that now exist. It may
be possible to meet these objectives through developments in genetic sequencing
technologies, which not only allow the production of genetic sequence data at
lower cost to low- and middle-income countries, but also leverage new high-
throughput sequencing technologies (broadly referred to as next generation
sequencing). 61 Together with so-called "big data" analytics, scientists
undertaking these efforts argue that mapping genomes of viruses, bacteria, and
other microbiological organisms will help humans prepare for the next pandemic
of a heretofore unknown viral pathogen, reveal mechanisms in the microbiome
that might facilitate the development of novel biotechnologies like new
medicines, and create more varieties of high-yielding, pest-resistant seeds that
reduce the environmental cost and increase the sustainability of agriculture.62
9 Abraham Sunday Alabi et al, Enhanced Laboratory Capacity Development: A Boost for Effective
Tuberculosis Control in Resource-limited Settings, 56 INT'L J. INFECTIOUS DISEASES 81, 81-84 (2017).
o Global investments in Tuberculosis research and development: past, present and future, WHO (2017)
at 14, https://apps.who.int/iris/bitstream/handle/10665/259412/9789241513326-
eng.pdfjsessionid=85D5DE6DEDAF623F73B40D2769631B64?sequence=1.
61 Sam Behjati & Patrick S. Tarpey, What is Next Generation Sequencing?, 98 ARCHIVES DISEASE
CHILDHOOD EDUC. PRAC.EDrrioN 236, 236 (2013).
62 Id.; see generally Puma C. Kashyap, et al., Microbiome at the Frontier of Personalized Medicine, 92
MAYO CLINIC PROC. 1855 (2017) (predicting more precise targeting of pathogens through next
generation sequencing and large-scale biogenomic projects); Rajeev K. Varshney et al., Harvesting the
Promising Fruits of Genomics: Applying Genome Sequencing Technologies to Crop Breeding, 12 PLOS
BIOLOGY 1 (2014) (predicting that advances in next generation sequencing will lead to more precise
identification of beneficial traits in breeding crops).
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A. The Proliferation of Genetic Sequencing Technologies and
Collaborative Partnerships
These possibilities exist largely because of the plummeting cost of genetic
sequencing and analysis technologies. The first human genome took US$2.7
billion and almost 15 years to complete. 63 Now, genome sequencing and analysis
cost around US$1,400. 64 The sequencing can be done in a few days, and analysis
in a few weeks. 65 The decline in cost is often compared to Moore's Law in the
semi-conductor sector. According to Moore's hypothesis, unit cost per circuit
component falls as the number of components in an integrated circuit increase.
66
The (largely accurate) prediction is that as integrated circuits increase in
complexity, they decrease in cost. With respect to genetic sequencing, the trend
is even more dramatic [See Figure 1].




6 Chris A. Mack, Fifty Years of Moore's Law, 24 IEEE TRANSACTIONS SEMICONDUCTOR




While the availability of sequencing technologies and associated
laboratory capacity remain concentrated in wealthier countries, there is already
significant progress toward establishment and maintenance of that capacity in
low- and middle-income countries. According to a 2015 analysis, 20 of the
world's 603 international laboratories offering genetic testing were in middle-
income and none were in low-income countries.6 8 An analysis by Mohamed
Helmy, Mohamed Awad, and Kareem Mosa showed that in the majority of
developing countries outside of Africa there are at least 1-10 genetic sequencing
projects underway and in many low- and middle-income countries, there are
entire centers devoted to such research.69
67 The Cost of Sequencing a Human Genome, NAT'L HUMAN GENOME RES. INST.,
https://www.genome.gov/about-genomics/fact-sheets/Sequencing-Human-Genome-cost (last updated
Oct. 24, 2019).
68 Fasil Tekola-Ayele & Charles N. Rotimi, Translational Genomics in Low and Middle Income
Countries: Opportunities and Challenges, 18 PuB. HEALTH GENOMiCS 242, 243 (2016).
69 Mohamed Hemly et al., Limited Resources of Genome Sequencing in Developing Countries:
Challenges and Solutions, 9 APPLIED & TRANSLATIONAL GENOMICS 15, 17 (2016).
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These projects and centers are rarely stand-alone investments made by
governments. Rather, they have emerged through joint-ventures, public-private
partnerships, and international development programs. For example, the African
Center of Excellence for Genomics of Infectious Diseases (ACEGID) at
Redeemer's University (Nigeria) was established with the support of the World
Bank and the U.S. National Institutes of Health to serve several institutions in
the surrounding region, including Senegal, Nigeria, and Sierra Leone.70 The
Genome Science Program at the Los Alamos National Laboratory, USA and
research institutions in several developing countries including Jordan, Uganda,
and Gabon is similarly aimed at developing genomic research capacity in low-
and middle-income countries, which typically contribute tailored levels of
funding, equipment, and training.7 1
This benefit has materialized in a relatively short period of time.
ACEGID-established laboratories and researchers performed the first diagnosis
of Ebola virus disease in Nigeria and Sierra Leone and were able to track its
origin and evolution in West Africa.72 ACEGID scientists partnered with
physicians from the Irrua Specialist Teaching Hospital in Nigeria to sequence
and quickly contain a recent outbreak of Lassa fever.73 The Genome Science
Program generates a positive "impact [on] almost all areas of the life sciences
and presents opportunities for technology and economic development.
74
Indeed, many of the current large-scale biogenomic efforts began with
government-to-government cooperation on scientific research relevant to human
health and nutrition. The Global Virome Project (see Part III A), which aims to
identify unknown future viral threats through the development of a
comprehensive ecologic and genetic database of virtually all naturally-occurring
viruses, originated with the PREDICT project based at the University of
California-Davis, which established genetic sequencing partnerships with
scientists in 31 countries.7 5 The EU project Micro B3 (Marine Microbial
Biodiversity, Bioinformatics, Biotechnology) (see Part III C) "develops
innovative bioinformatic approaches and a legal framework to make large-scale
data on marine viral, bacterial, archaeal and protist genomes and metagenomes
accessible for marine ecosystems biology and to define new targets for
biotechnological applications." 76  Micro B3 builds upon a highly
interdisciplinary consortium of 32 academic and industrial partners comprising
70 Onikepe A Folarin, Anise N. Happi & Christian T. Happi, Empowering African Genomicsfor
Infectious Disease Control, 7 GENOME BIOLOGY 515, 515 (2014).
71 Helen H. Cui, et al., Building International Genomics Collaboration for Global Health Security, 3
FRONTIERS PUB. HEALTH 1, 1-8 (2012).
72 Stephen K. Gire, et al., Genomic Surveillance Elucidates Ebola Virus Origin and Transmission
During the 2014 Outbreak, 345 SCl. 1369, 1369 (2014).
7' B. David Zarley, How a Nigerian Genome Team Contained a Lassa Fever Outbreak With
International Partners, QUARTZ AFRICA (Mar. 27, 2019), https://qz.com/aftica/ I580888/lassa-fever-
outbreak-contained-by-nigerian-genome-team/.
71 Cui, supra note 71, at 3.75 About PREDICT, UC DAVIS VET. MED., https://ohi.vetmed.ucdavis.edu/programs-projects/predict
project/about (last visited Nov. 13, 2019).
76 The Micro B3 Project, MICRO 3, https://www.microb3.eu (last visited Nov. 13, 2019) [hereinafter The
Micro B3 Project homepage].
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world-leading experts in bioinformatics, computer science, biology, ecology,
oceanography, bioprospecting and biotechnology. Yet these biogenomic
projects, and the partnerships that undergird them, are emerging in a distinctly
new legal and ethical milieu than did the Green Revolution or biomedical
research over most of the twentieth century.
B. Accessing Genetic Resources: Historical Models
Unlike past international collaborations, every step of the scientific process
now faces a significantly changed ethical and legal landscape. Where previous
collaborations were accomplished through informal transfer of the required
genetic resources (e.g. a researcher has a colleague in host country send
biological samples to labs in Europe or North America, annexed research sites,
or "parachute" acquisition), scientific teams must now navigate laws and
regulations passed pursuant to the Convention on Biological Diversity and its
implementing Nagoya Protocol, which requires that parties obtain the prior
informed consent of providing countries before commencing research on their
genetic resources and that benefits associated with that research be shared
according to mutually agreed terms. 77 This regulatory mechanism is known as
access and benefit-sharing (ABS). The following discussion provides in greater
detail how research was formerly conducted, and the changes ushered in by the
Convention on Biological Diversity and the Nagoya Protocol.
1. Transfer of Samples between Collaborators
The scientific method requires verification of other scientists' research
results, access to inputs like reagents (in the biological sciences), and sharing of
results for replication and future research.78 This necessitates a level of openness
and sharing of research materials used to conduct original experiments. Scientific
norms encourage researchers to share samples and laboratory reagents with each
other for the purposes of verification and furthering the scientific endeavor as a
whole.79 Therefore, scientists will often informally share their biological samples
with other scientists. Informal transfer is also common in citizen science projects
where members of the public collect samples in their own country and send those
samples to scientific researchers in other countries.
Under this model, as it prevailed over the course of the twentieth century,
researchers, largely based in wealthy countries, received biological samples from
colleagues in low- or middle-income countries, sometimes with the
understanding that some other resource or knowledge would be shared in
77 The FAO's International Treaty on Plant Genetic Resources for Food and Agriculture also influences
these partnerships where they cover one of the 35 food crops or 29 forages listed in Annex I of the
treaty. Similarly, enhanced biosecurity regulations also influence the transfer of biological material.
78 NATIONAL ACADEMY OF SCIENCES ET AL., 1 RESPONSIBLE SCIENCE: ENSURING THE INTEGRITY OF
THE RESEARCH PROCESS 36 (1992).
79 Id.
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return.80 Indeed, this is how samples of the Middle East Respiratory Syndrome
coronavirus (MERS-CoV) were transferred to the Erasmus Medical Center in
the Netherlands. 81 Ali Mohamed Zaki, an Egyptian physician working in Saudi
Arabia, contacted scientists at Erasmus for technical help after he suspected a
novel virus caused the severe respiratory symptoms, renal failure, and death of a
patient.82 According to Zaki:
[Erasmus] confirm[ed] my initial findings and asked me to
send them a small portion of patient zero's sample because
they wanted to do some more testing and they were running
out of RNA. I didn't have any mechanism to ship a live virus
sample while maintaining the cold chain during transit. So, I
filtered the sputum sample and mixed the filtrate with Vero
cells, packaged the tightly capped tube in appropriate
biohazard containers and shipped it with a private carrier at
room temperature as a diagnostic sample. It worked. They
received it in the Netherlands and managed to recover the live
virus, the first genetic analysis of this novel virus published in
New England Journal of Medicine.83
These sorts of informal sharing practices were common over the course of
the 1960s, 1970s, and 1980s and, given many researchers lack knowledge about
changes in national and international law, almost certainly continue to some
extent today.
As a result of new norms introduced by the Convention on Biological
Diversity and the Nagoya Protocol discussed below, transfers of samples are now
unlikely to occur between the parties without the conclusion of Material Transfer
Agreements (MTAs). MTAs are usually standardized forms, outlining what the
user party can and cannot do with the transferred materials (and may include
limitations on commercial use or applying for intellectual property rights), which
party, if any, has ownership rights over the materials, and whether or not those
rights are transferrable.84 The transfer of genetic resources between colleagues
is likely to remain an important source of samples for scientific research,
although domestic regulations implementing the CBD and Nagoya Protocol have
led to these transfers becoming increasingly formalized.
2. Parachute Acquisition of Host Country Samples
'0 Clare Dyer & Owen Dyer, WHO to Probe Claims that Dutch Scientists Restricted Access to Novel
Coronavirus, 346 BMJ 1 (2013); Sam Halabi, Viral Sovereignty, Intellectual Property, and the
Changing Global System for Sharing Pathogens for Infectious Disease Research, 28(1) ANNALS OF
HEALTH L. 101, 106-07 (2019).
"I Dyer, supra note 80, at 1.
12 Islam Hussein, The Story of the First MERS Patient, NATURE MNDDLE EAST (June 2, 2014),
https://www.natureasia.com/en/nmiddleeast/article/10. 1 038/nmiddleeast.2014.134.
83 id.
84 Philip Mirowski, Livin 'with the MTA, 46 MINERA 317, 318 (2008).
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Parachute acquisition, often referred to simply as "field work," is the
collection of genetic resources in the host nation by a foreign researcher who
later returns to his or her home country to conduct research on the collected
samples. Given that the use of natural resources for their genetic components
requires a minute quantity of genetic material, such collection activities can be
extremely difficult to detect.85 Parachute acquisition is often discovered to have
occurred in cases of egregious misappropriation of a host nation's genetic
resources and where there is a great deal of money involved. For example, in the
early 2000s, French researchers conducted interviews in French Guiana as part
of their investigation into antimalarial compounds, including those derived from
the Quassia amara tree.86 Their research was published in 2005.87 In 2015, the
researchers obtained a patent on a compound derived from the Quassia
amara that had antimalarial properties. 88 While apparently undetected for many
such transfers, these kinds of issues become significant at the time of
downstream product commercialization, and many countries now require that
the origin of genetic resources be disclosed in patent applications.
As with informal transfer, parachute acquisition is now widely viewed as
"biopiracy." 89 The "unidirectional flow of samples" out of low- and middle-
income countries and into wealthy nations for both commercial and non-
commercial research and development has "impacted negatively [] the
development of local capacity, infrastructure and expertise." 90 Parachute
acquisition without first obtaining prior informed consent from the host
government is no longer generally accepted as a method for collecting biological
samples, even if those samples are being used for non-commercial purposes. This
exploitative practice precipitated some of the formalizing measures, such as
requiring MTAs, which now govern the terms under which samples are
transferred out of the host country's jurisdiction.91
3. Annexed Research Sites for the Collection of New Samples
Although less used than informal transfer and parachute acquisition,
annexed research sites in the provider country provide another method for
obtaining local genetic resources.92 This method means that samples of genetic
s Florian Rabitz, Biopiracy After the Nagoya Protocol: Problem Structure, Regime Design and
Implementation Challenges, 9 BRAZ. POL. SCI. REv. 30, 38-39 (2015).
86 Janna Rose, Biopiracy: When Indigenous Knowledge is Patented for Profit, THE CONVERSATION




90 C. Staunton & K. Moodley, Data Mining and Biological Sample Exploration from South Africa: A
New Wave ofBioexploitation Under the Guise of Clinical Care?, 106 S. AFR. MED. J. 136 (2016).
91 Daniel F. Robinson, Locating Biopiracy: Geographically and Culturally Situated Knowledges, 42
ENv'T & PLAN. 38, 47 (2010).
92 See, e.g., Material Transfer Agreement on Plant Genetic Resources for Food and Agriculture
"National Programme on Plant Genetic Resources and Agro-biodiversity Conservation and
20201
THE YALE JOURNAL OF INTERNATIONAL LAW
resources are collected locally, and that at least part of the research on these
genetic resources is conducted within the host country. This collection and
research can be done by foreign or local researchers. Providing that there is no
transboundary movement of genetic resources, this practice may technically
exist outside of the remit of the CBD and Nagoya Protocol detailed infra. At
their best, annexed research sites encourage the active participation of partners
within the provider country to foster international collaboration, conduct
training, share expertise, engage in technology transfer, and help build scientific
capacity in the host nation.93 Some countries have implemented laws that require
foreign scientists to engage with the local scientific community even if they do
not intend to transfer any biological resources outside of the host country. Brazil,
for example, requires foreign researchers to register with a local partner before
commencing research activities.94 At their least helpful, annexed sites may be
established, funded, and staffed entirely by foreign research entities, contributing
little to local research capacity, and perhaps sharing little in terms of the benefits
that result from research.
C. The Changing International Legal Landscape for Accessing Genetic
Resources
The models for obtaining genetic resources enumerated supra
flourished when the prevailing paradigm in scientific research was openness and
sharing, and the resources under study-seeds, plants for agriculture, and other
biological resources-were viewed as the "common heritage" of humanity.
95
While this paradigm facilitated research generally, it did not necessarily do so
equitably or ethically. Eventually, the dynamics of these kinds of biological
research collaborations-in which the benefits of the research flowed to and
largely stayed in European and North American countries where advanced
technology for analysis and products were located-became intertwined with
larger international legal movements. In 1964, the U.N. General Assembly
established the United Nations Conference on Trade and Development
(UNCTAD) to pursue trade-related development policies that would be more
favorable to developing countries. 96 UNCTAD existed to "maximize
the trade, investment and development opportunities of developing
countries and assist them in their efforts to integrate into the world economy on
Utilization " of the Czech Republic, Czech Gene Bank, CRI, WORLD INTELL. PROP. ORG.,
https://www.wipo.int/tk/en/databases/contracts/texts/crgenebank.html (last visited Nov. 13, 2019).
" U.N. Conference on Trade & Dev., Facilitating Transfer of Technology to Developing Countries: A
Survey of Home-Country Measures, at 1, U.N. Doc. UNCTAD/ITE/IPC/2004/5 (2004).
14 David Smith et al., Explanation of the Nagoya Protocol on Access and Benefit Sharing and Its
Implication for Microbiology, 163 MICROBIOLOGY 289, 294-95 (2017).
95 See e.g., INT'L UNION FOR CONSERVATION OF NATURE, ACCESSING BIODIVERSITY AND SHARING THE
BENEFITS: LESSONS FROM IMPLEMENTING THE CONVENTION OF BIOLOGICAL DIVERSITY 1 (Santiago
Carrizosa et al., eds., 2004).
96 JOHN TOYE, UNCTAD AT 50: A SHORT HISTORY 3-4, 14 (2014).
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an equitable basis."97 Shortly after its formation, UNCTAD began to focus on
technology transfer as a crucial priority for development.98
Control over natural resources was also prioritized.99 On April 19, 1972,
Mexican President Luis Echeverria Alvarez urged the adoption of a Charter of
Economic Rights and Duties of States aimed at exerting greater authority over
natural resources.100 At the time, those resources were thought to be mostly
commodities like petroleum, rubber, and agricultural goods. 10 1 However, the
general call for control over natural resources later expanded in the late 1980s to
include genetic and microbiological resources.10 2
In 1972, the United Nations also held the first of many global
conferences on the Human Environment in Stockholm, Sweden.103 In the decade
after the 1972 conference, scientists and non-governmental organizations
identified biodiversity as a pressing environmental question.104 The threats to the
rainforests in the Amazon basin-logging, extraction, agriculture-illustrated
the rapid loss of crucial biological resources.10 5 In 1987, the Governing Council
of the United Nations Environmental Programme (UNEP) created a working
group to develop a legally binding treaty to protect biological resources.10 6 In
1991, formal multilateral negotiations began on a Convention for Biological
Diversity. 107
Eventually these preparations led to the 1992 U.N. Conference on
Environment and Development (or "Earth Summit"), held in June 1992 in Rio
De Janeiro, the outcome of which included the Convention on Biological
Diversity (CBD).10 8 The CBD descended not only from environmental
conferences but also from the 1962 United Nations General Assembly's
97 U.N. Conference on Trade and Dev., UNCTAD in Brief, U.N. Doc. UNCTAD/EDM/17/REv.1 (2016).
" U.N. Conference on Trade and Dev., 2d Sess., at 353-55, U.N. Doc. TD/97 (1968).
99 Charles N. Brower & John B. Tepe Jr., The Charter of Economic Rights and Duties of States: A
Reflection or Rejection of International Law?, 9 INT'L. LAWYER 295, 296 (1975).100 
Id
101 U.N. Conference on Trade & Dev. Secretariat, Trade and Development Report, at 32, U.N. Dc.
UNCTAD/TDR/2/Rev. 1 (1982).
112 Jonathon 13. Tucker, Biosecurity: Limiting Terrorist Access to Deadly Pathogens, U.S. INST. OF
PEACE 27 (2003), https://www.usip.org/sites/default/files/pwks52.pdf.
103 United Nations Conference on the Human Environment, U.N. SUSTAINABLE DEv.,
https://sustainabledevelopment.un.org/milestones/humanenvironment (last visited Nov. 13, 2019).
"
0 6 Daniel H. Janzen, The Future of Tropical Ecology, 17 ANN. REV. ECOLOGY & SYSTEMATICS 305,
305-306 (1986); see generally Josd Luiz de Andrade Franco, The Concept of Biodiversity and the
History of Conservation Biology, 32 HISTORIA 21, 21-25 (2013) (explaining the history of the rise of
biodiversity as a scientific concern).
"'5 See generally Michael J. Heckenberger et al., The Legacy of Cultural Landscapes in the Brazilian
Amazon: Implications for Biodiversity, 362 PHIL. TRANSACTIONS ROYAL SOC'Y B: BIOLOGICAL SCI.
197, 197-208 (2007); see also Christopher Uhl & Ima Celia Guimaraes Vieira, Ecological Impacts of
Selective Logging in the Brazilian Amazon: A Case Study from the Paragominas Region of the State of
Peru, 21 BIOTROPICA 98, 98-106 (1989).
106 U.N. GAOR, 42d Sess., 96th plen. mtg. at 139, U.N. Doc. UNEP/GC.14/17 annex III (1987).
107 History of the Convention, CONVENTION ON BIOLOGICAL DIVERSITY, https://www.cbd.int/history/.
1d; see generally U.N. Conference on Env't & Dev., Rio Declaration on Environment and
Development, U.N. Doc. A/CONF.151/26, Vol. 1 (1992).
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Declaration on Permanent Sovereignty over Natural Resources, which asserted
that it was the inalienable right of each state to handle natural resources as they
saw fit and that any profits resulting from the use of these resources should be
shared "between investors and the recipient state."
109
The CBD established that developing countries should not only control
access to genetic resources, but also benefit from any commercial value
generated from their utilization. " 0 The CBD adopted as one of its objectives the
promotion of conservation and sustainable use of biological diversity, while
seeking "fair and equitable" sharing of benefit derived.11 The CBD's goal of
"access and benefit sharing" includes both plant genetic resources as well as the
relevant technology associated with their development.1 12 It also codified the
protection of indigenous peoples and the traditional knowledge they had
developed especially for medical and agricultural applications, including a
principle of compensation when firms or others commercialized that
knowledge. 113 The CBD created a legal zone in which biodiverse countries could
set terms for exploitation and the protection of their citizens to share in the
benefits of any commercialization of their resources. 14 More than 39 nations
have created Access and Benefit Sharing (ABS) regimes via their domestic laws,
with particular activity from biodiverse states like Brazil, China, Costa Rica, and
South Africa. 115
1. Article 15 of the CBD Established Sovereign Rights over Genetic
Resources and Their Exploitation
Article 1 of the CBD requires the "fair and equitable sharing of the
benefits arising out of the utilization of genetic resources," a phrase that gave
rise to a great deal of uncertainty, even as it shaped national "bioprospecting"
laws. 116 The CBD reaffirmed "the sovereign rights of States over their natural
resources" and recognized that "the authority to determine access to genetic
resources rests with the national governments and is subject to national
legislation." 17 "Genetic resources" are defined as "genetic material of actual or
'09 G.A. Res. 1803 (XVII), at 15 (Dec. 14, 1962).
10 Convention on Biological Diversity, June 5, 1992, 1760 U.N.T.S. 79 [hereinafter CBD]. There are
198 States party to the CBD. The United States is not a party.
... CBD, supra note 110, art. 1.
12 Jonathan Carr, Agreements that Divide: TRIPS vs. CBD and Proposals for Mandatory Disclosure of
Source and Origin of Genetic Resources in Patent Applications, 18 J. TRANSNAT'L L. AND POLICY 131,
133 (2008).
11 CBD, supra note 110, art. 8.
"4 Michiel Korthals & Brain De Jonge, Two Different Ethical Notions of Benefit Sharing of Genetic
Resources and Their Implications for Global Development, 28 NEw GENETICS AND Soc'y 87, 88
(2009).
.. Nicolas Pauchard, Access and Benefit Sharing under the Convention on Biological Diversity and Its
Protocol: What Can Some Numbers Tell Us about the Effectiveness of the Regulatory Regime?, 6
RESOURCES 1,11 (2017).
116 CBD, supra note 110, art. 1; Thomas A. Kursar, What Are the Implications of the Nagoya Protocol
for Research on Biodiversity?, 61 BIoSCIENCE 256, 256-57 (2011) (discussing the imperfect
implementation of CBD in an attempt to improve biodiversity).
117 CBD, supra note 110, art. 15(1).
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potential value" and "genetic material" means "any material of plant, animal,
microbial or other origin containing functional units of heredity." '118 The treaty's
governing body, the Conference of the Parties (COP), has excluded human
genetic resources from the scope of the CBD, but the definition of "genetic
resources" still captures most, if not all, non-human genetic resources of interest
to scientists in the biology-based disciplines.
In accordance with the CBD, the "countries of origin" of genetic resources
119
must "facilitate access to genetic resources for environmentally sound uses.,
120
The "country of origin of genetic resources" is defined as "the country which
possesses those genetic resources in in-situ conditions," that is, "conditions
where genetic resources exist within ecosystems and natural habitats."
'121
Accessing genetic resources within other countries' jurisdictions "shall be
subject to prior informed consent" of the provider 122 and "shall be on mutually
agreed terms." 123 The ultimate objective of these provisions was to enable
biodiverse countries to secure a share in the "benefits arising from the
commercial and other utilization of genetic resources. 124 In short, this was a
grand bargain of access to genetic resources in exchange for sharing the benefits
derived from utilizing those genetic resources. Access to genetic resources and
the sharing of the associated benefits has been termed "access and benefit-
sharing" (ABS) within the regulatory framework of the CBD. The CBD is a
"framework convention" setting the broad parameters for agreement between
and within the Contracting Parties then implementing their own legislation,
administration, and policies to give effect to their CBD commitments.
Before 2010, CBD Article 15 had been largely guided by the non-
binding Bonn Guidelines on Access to Genetic Resources and Fair and
Equitable Sharing of the Benefits Arising out of Their Utilization.1 25 The Bonn
Guidelines recommended the following provisions for contracts between
sovereign states and research entities:
(a) Regulating the use of resources in order to take into
account ethical concerns of the particular Parties and
stakeholders, in particular indigenous and local communities
concerned;
(b) Making provision to ensure the continued customary use
of genetic resources and related knowledge;
118 Id. art. 2.
119 1d. art. 15(3).
12 Id. art. 15(2).
121 Id. art. 2.
'Id. art. 15(5).
3Id. art. 15(4).
124 1d. arts. 1, 15(7).
125 U.N. Conference on Trade & Dev., The Convention on Biological Diversity and the Nagoya
Protocol: Intellectual Property Implications, 11, U.N. Doc. UNCTAD/DIAE/PCB/2014/3 (2016).
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(c) Provision for the use of intellectual property rights include
joint research, obligation to implement rights on inventions
obtained and to provide licenses by common consent;
(d) The possibility of joint ownership of intellectual property
rights according to the degree of contribution. 
126
2. The Nagoya Protocol Clarified Conditions for Researchers 'Access to
Genetic Resources and the Sharing of Benefits Arising from their
Study and Development
The 2010 Nagoya Protocol on Access to Genetic Resources and the Fair and
Equitable Sharing of Benefits Arising from Their Utilization (Nagoya Protocol)
aimed to encompass the broader universe of drugs, medical therapies,
agrochemical products, vaccines and other products derived from genetic
resources not clearly governed by the CBD. 127 The Nagoya Protocol, formed to
give specific content to Article 15 of the CBD, regulates access to genetic
resources in party states and establishes mechanisms for fair and equitable
sharing of benefits arising out of the utilization of genetic resources. 128 It is
committed to the equitable sharing of research collaborations and ensuing
benefits. 12
9
Countries adopting legislation or regulation pursuant to the treaty ensure
that access to any genetic resources within the territory of that country is
conditioned on prior informed consent not only of the country of origin but also
"[i]n accordance with domestic law," and the consent of indigenous and local
communities. 130 Moreover, once access to genetic resources results in a
commercially viable product:
benefits arising from the utilization of genetic resources as well
as subsequent applications and commercialization shall be
shared in a fair and equitable way with the Party providing such
resources that is the country of origin of such resources or a
Party that has acquired the genetic resources in accordance with
the Convention.
31
The precise nature of benefit-sharing, both monetary and non-monetary, is left
to the states themselves to negotiate with those who generate commercialized
products. As discussed in Halabi's Intellectual Property:
126 Konstantia Koutouki & Katharina Rogalla von Bieberstein, The Nagoya Protocol: Sustainable
Access and Benefits-Sharing for Indigenous and Local Communities, 13 VT. J. ENVTL. L. 513, 522-23
(2011).
27 Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits
Arising from their Utilization to the Convention on Biological Diversity, Oct. 29, 2010,
UNEP/CBD/COP/DEC/X/I [hereinafter Nagoya Protocol].
128 Kursar, supra note 116, at 256-57.
129 Evanson Chege Kamau et al., The Nagoya Protocol on Access to Genetic Resources and Benefit
Sharing: What Is New and What Are the Implications for Provider and User Countries and the
Scientific Community? 6 L., ENV'T & DEV. J. 246,249 (2010) [hereinafter Kaman, What Is New].
30 Nagoya Protocol, supra note 127, art. 7.
131 Id. art. 5.
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The economic purpose of the Nagoya Protocol was explicit.
The CBD as it was initially formed lacked a legal framework
for cross-border application of its rules. User country
governments were not obligated to address complaints or assist
others. After six years of negotiations, the Nagoya Protocol
brought "greater legal certainty and transparency" regarding
the exchange of genetic resources while "reaffirm[ing] and
clariffying] the [CBD's] broad economic scope." It further
addressed issues concerning scientific research, also neglected
by the CBD and created new enforcement provisions for user
and provider nations to implement within their respective
national legal systems.1
32
Before the Nagoya Protocol, the non-binding Bonn Guidelines on Access to
Genetic Resources and Fair and Equitable Sharing of the Benefits Arising out of
Their Utilization, a set of voluntary guidelines issued subsequent to the
Convention on Biological Diversity but before Nagoya, guided implementation
of CBD Article 15.133 The Nagoya Protocol entered into force on October 12,
2014, and has 116 Parties.' 34 The Nagoya Protocol defmes "[u]tilization of
genetic resources" as "research and development on the genetic and/or
biochemical composition of genetic resources, including through the application
of biotechnology."' 135 The term "research and development" (R&D) is not further
defined so the term should be understood to embody its ordinary meaning.' 36
Any use of the genetic resources, including the generation and analysis of genetic
sequence data could therefore qualify as "utilization of genetic resources" within
the remit of the CBD and Nagoya Protocol.
Benefits provided in exchange for accessing and utilizing genetic resources
can be monetary, which could include an up-front payment for an access permit
or the payment of royalties on any resulting commercialized products. 13 7 Such
monetary benefits may be the appropriate form of benefit-sharing when the users
are conducting research and development with commercial intent. Non-
monetary benefits may be better suited when the research is non-commercial
(academic research), and can include the sharing of relevant research results,
sharing of technology and knowledge, collaboration with local scientists or
education and training. 138 The essence of ABS under the CBD and Nagoya
132 Halabi, Intellectual Property, supra note 4, at 176.
133 Conference of the Parties to the Convention on Biological Diversity, Sharing of the Benefits Arising
out of their Utilization, SECRETARIAT OF THE CONVENTION ON BIOL. DIVERSITY (2002).
134 Parties to the Nagoya Protocol, CONV. ON BIOL. DIVERSITY, https://www.cbd.int/abs/nagoya-
protocol/signatories/ (last visited Nov. 13, 2019).
... Nagoya Protocol, supra note 127, art. 2.
136 Evanson Chege Kamau & Gerd Winter, Research and Development under the Convention on
Biological Diversity and the Nagoya Protocol, in 1 RESEARCH AND DEVELOPMENT ON GENETIC
RESOURCES: PUBLIC DOMAIN APPROACHES IN IMPLEMENTING THE NAGOYA PROTOCOL 31-32 (Evanson
Chege Kamau et al. eds., 2017).
137 Nagoya Protocol, supra note 127, Annex.
138 id.
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Protocol is that the party accessing genetic resources reach prior informed
consent and mutually agreed terms with the providing party and the benefits
shared reflect their particular circumstances.
To reiterate, those conducting research with non-commercial intent are still
expected to abide by the host nation's ABS rules. However, Parties have been
encouraged to implement "simplified measures on access for non-commercial
research purposes."'1 39 The Nagoya Protocol recognizes that in some cases, what
started out as non-commercial research will lead to the development of a
marketable product or process and requires Parties to the Nagoya Protocol to
take "into account the need to address a change of intent."' 40 This may require
the user to renegotiate benefit-sharing obligations with the provider to better
reflect that new utilization. When such a provision is included in the original
mutually agreed terms, this is referred to as a "come-back clause."'
14 1
The effect of the CBD and the Nagoya Protocol is that there are a variety of
domestic rules and regulations for accessing genetic resources all around the
world. Some countries are operating under the ABS regime outlined in the CBD,
others have agreed to comply with both the CBD and the Nagoya Protocol, and
others still are yet to implement domestic ABS laws despite being Party to one
or both of these instruments. There are definitional ambiguities and unclear
provisions in both the CBD and Nagoya Protocol, but as a minimum, users can
expect that they will have to seek the prior informed consent (PIC) of the
providing authority and establish mutually agreed terms (MAT) before accessing
or utilizing the provider's genetic resources. It is essential that parties wishing to
collect or utilize genetic resources originating in other countries consult the
National Focal Point (NFP), i.e. the regulatory authority charged with referring
biological research efforts to the appropriate agency (Competent National
Authority, or CNA) of the originating country to ensure researchers are fully
aware of and compliant with domestic laws. 142
The Nagoya Protocol requires its Parties to put in place measures ensuring
that users within their jurisdiction have accessed genetic resources (and any
traditional knowledge of Indigenous Peoples and local communities that is
associated with genetic resources) in compliance with the provider nation's ABS
rules. 143 Non-compliance can result in more than just reputational damage to the
researchers involved. In some jurisdictions, non-compliance will attract penalties
under civil law (e.g., fines) and even prosecution under criminal law. 44
139 Id. art. 8(a).
140 id.
141 Kamau, What Is New, supra note 129, at 256.
142 Caroline von Kries et al., Micro B3 Model Agreement on Access to Marine Microorganisms and
Benefit Sharing: Text and Commentary, in RESEARCH AND DEVELOPMENT ON GENETIC RESOURCES:
PUBLIC DOMAIN APPROACHES IN IMPLEMENTING THE NAGOYA PROTOCOL 335-36 (Evanson Chege
Kamau et al. eds., 2017) [hereinafter Annotated Model Agreement].
14' Nagoya Protocol, supra note 127, arts. 15(1), 16(1).




The laws of China, France (French Guiana), India, and South Africa provide
good examples of how enforcement operates. Under Chinese law adopting the
Nagoya Protocol, "genetic resources should be restricted to use in China, and the
research should include the participation of a Chinese party., 145 China
encourages the parties to engage in cooperative research projects to register the
intellectual property of the inventions that emerge from that research in China.
A recent study notes that:
China's Ministry of Environmental Protection led a number of
other government ministries in issuing a Notice on Enhancing
the Access and Benefit-Sharing of Biological Genetic
Resources in the Cooperation and Communication with
Foreign Parties in October 2014. This Notice requires
government approval for foreign parties (1) bio-prospecting in
natural conservations and (2) to remove certain of those
resources deemed highly valuable from China. Plans are
underway to issue a more detailed regulation on acquiring and
utilizing genetic resources in the near future.146
Similarly, in the context of India, the same study notes that:
India imposes access requirements on "biological resources"
for research and commercial purposes on entities that are not
incorporated in India. Authorisations from the National
Biodiversity Authority may be required (i) to obtain biological
resources from India, (ii) to apply for a patent on results of
R&D on the resources, or (iii) to transfer the biological resource
as well as the results of the research. The National Biodiversity
Authority may oppose the grant of IP rights linked to Indian
biological resources or associated traditional knowledge.
Indian law grants the authority the power to do so around the
globe. 147
Like India and China, South Africa maintains a system of notifications
and permits that distinguish between the discovery and commercialization of
indigenous biological resources. Foreign companies and other persons may
apply for a permit to bio-prospect, but must do so jointly with South African
entities. The aforementioned study notes that "[w]ith the recent amendments of
May 2015, bio-prospecting and bio-trading without a permit can be fined by up
4"Global Enforcement of the Nagoya Protocol in Life Sciences Industries, COVINGTON & BURLING
LLP 2 (2016), https://www.cov.com/-
/media/files/corporate/publications/2016/12/global enforcement of the nagoya-protocol in life scien
ces industries.pdf [hereinafter Covington Report].
146 Id. at 2.
141 Id. at 2-3.
2020]
THE YALE JOURNAL OF INTERNATIONAL LAW
to five or even ten million rand (around US$700,000), or a fine 'equal to three
times the commercial value of the activity in respect of which the offence was
committed, whichever, is the greater. (Regulation 42(2))"'. 148
In August 2016, a new French law entered into force, creating the
French Agency for Biodiversity. t49 The law ratified the Nagoya Protocol and
established a system for authorizing access to genetic resources under the
jurisdiction of France. 5° In the case of France, the above study notes that:
The law states that financial benefit-sharing is calculated on the
global turnover realized from the product derived from the
genetic resource, capped at 5 percent. The access permit may
be refused if the proposed benefit-sharing by the applicant
"manifestly" does not correspond to its financial capacity. The
new access legislation replaces the region-specific rules that
already existed for the Amazonian Forest National Park in
French Guyana. 151
a. Obtaining Prior Informed Consent and Agreeing to Terms under
the Nagoya Protocol
The first step to ensure compliance usually entails contacting the NFP
to obtain information and approaching the Competent National Authority (CNA)
- which may be a Ministry of Environment, Ministry of Health, Ministry of
Science and Technology, or other ministry of the provider country - to obtain
PIC and establish MAT prior to obtaining any new materials. In some cases,
CNAs will issue permits or Internationally Recognized Certificates of
Compliance (IRCCs) which "serve as evidence that the genetic resource which
it covers has been accessed in accordance with [PIC and MAT] as required by
the domestic [ABS] legislation or regulatory requirements of the Party providing
[PIC]. '152 The terms of the agreement normally outline how the samples are to
be used and stored, whether the samples can be retained beyond the duration of
the initial project, whether they should be returned to the provider or destroyed,
and whether the samples or any subsamples (derived from the original samples)
can be transferred to third parties and under what conditions. 53 Terms may also
cover how to deal with changes of intent (from non-commercial research to
commercial product development) and any intellectual property considerations.
Benefit-sharing terms will need to cover items such as how the research results
148 id.
9 Reclaiming biodiversity, nature and landscapes, GOUVERNEMENT.FR, (Aug. 22, 2016)
https://www.gouvernement.fr/en/reclaiming-biodiversity-nature-and-landscapes.
"0 Covington Report, supra note 145, at 3.
15 1 Id.
152 Nagoya Protocol, supra note 125, art. 17(3).
153 See, e.g., Global Genome Biodiversity Network, Guidance: Best Practice for Access and Benefit-





will be disseminated, how related data will be managed, and how the provider
country ought to be acknowledged in research publications.
For one-off collecting activities and short-term projects, obtaining
permits or IRCCs for each individual sample may be achievable. However, this
may not be efficient for long-term collaborations or "big science" projects. The
Global Genome Biodiversity Network, a global consortium of organizations
supporting the collection, maintenance and sharing of research-quality genomic
specimens, has established best practice guidelines for ABS for the collection of
biological materials, stating that "[i]n cases where an institution conducts long-
term or repeated project[s] in certain Providing Countries, it might be beneficial
to develop framework agreements between the National Competent Authorities
of the involved countries." 154 Part III will analyze four large-scale international
biogenomic research collaborations, providing case studies on how they have
addressed ABS when obtaining multiple samples for both commercial research
and development as well as for purely non-commercial (academic) purposes in
multiple jurisdictions.
National jurisdiction includes the land and air column within the defined
territorial borders of a country, as well as its territorial waters and the exclusive
economic zone.1 55 In accordance with the CBD and Nagoya Protocol, countries
have the authority to exploit and regulate their genetic resources by
implementing domestic ABS legislative, administrative and policy measures. 156
Some countries are party to the CBD alone; others are party to the CBD and
Nagoya Protocol. Some countries have decided to implement relatively strict
regimes for accessing genetic resources within their territories, and others still
are yet to put any access controls in place. 57 All of this complicates the conduct
of scientific research that uses genetic resources from around the globe.
b. Micro-organisms as "genetic resources" under the CBD and
Nagoya Protocol
Some have argued that the unique properties of micro-organisms make
them inappropriate targets for regulation under the CBD and Nagoya Protocol's
ABS regime. 158 The third objective of the CBD is the same as the objective of
the Nagoya Protocol: "the fair and equitable sharing of the benefits arising out




.55 United Nations Convention on the Law of the Sea art. 2, Dec. 10, 1982, 1833 U.N.T.S. 397.
156 CBD, supra note 110, arts. 3, 15(1).
157 See Santiago Carrizosa, Diversity of Policies in Place and in Progress, in ACCESSING BIODIVERSITY
AND SHARING THE BENEFITS: LESSONS FROM IMPLEMENTING THE CONVENTION ON BIOLOGICAL
DIvERSrrY 9, 43-50 (Santiago Carrizosa et al. eds., 2004).
158 See, e.g., J6rg Overmann & Amber Hartman Scholz, Microbiological Research Under the Nagoya
Protocol: Facts and Fiction, 25 Sci. & Soc'Y 85, 85 (2017).
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of [or 'from'] the utilization of genetic resources," 159 indicating that these
instruments are not just about biodiversity conservation but also include issues
of equity and sustainable development. Whether or not they are suitable targets
for in situ conservation, micro-organisms and viruses plausibly fit the definition
of "genetic resources" under the CBD and Nagoya Protocol, and countries have
asserted their authority to regulate the ABS of micro-organisms in their domestic
laws.160 Still others have yet to take a position on the scope of the CBD and the
Nagoya Protocol with respect to micro-organisms. Acknowledging the
complexity of the various legal positions taken with respect to the matter, this
Article assumes for purposes of analyzing the legal and ethical questions at issue
that micro-organisms are within the scope of the CBD and the Nagoya Protocol.
c. Specialized International Instruments under the Nagoya Protocol
The Nagoya Protocol makes allowances for specialized instruments that
regulate ABS for specific genetic resources. The CBD and Nagoya Protocol do
not apply to specific subsets of genetic resources "[w]here a specialized
international access and benefit-sharing instrument applies that is consistent
with, and does not run counter to the objectives of the [CBD and Nagoya
Protocol]." 6 ' While not formally acknowledged as such, the World Health
Organization's Pandemic Influenza Preparedness Framework (PIP Framework)
bears many of the markers of such a specialized international instrument.
Adopted by the World Health Assembly in 2011 to regulate access to pandemic
influenza viruses through the WHO's Global Influenza Surveillance and
Response System (GISRS), the PIP Framework, through MTAs, regulates access
to influenza genetic resources and specifies the sharing of associated benefits
like pandemic influenza vaccines and antiviral medications. 162 The PIP
Framework does not include research and development activities that are
conducted outside of the GISRS, so any utilization of pandemic influenza viruses
outside of the PIP Framework is likely to be covered by the domestic laws that
countries have implemented to meet their obligations under the CBD and Nagoya
Protocol. 163 Similarly, the PIP Framework does not apply to seasonal influenza
viruses.
The U.N. Food and Agriculture Organization's International Treaty on
Plant Genetic Resources for Food and Agriculture, 2001 may serve as a
specialized international instrument for the crops and forages covered by the text
91 CBD, supra note 110, art. 1 ; Nagoya Protocol, supra note 127, art. 1.
160 See generally Michelle Rourke, Viruses for Sale: All Viruses are Subject to Access and Benefit-
Sharing Obligations Under the Convention on Biological Diversity, 39 EUR. INTELL. PROP. REV. 79
(2017) (explaining how the CBD and Nagoya Protocol have allowed States to assert sovereignty in
regulating genetic material).
161 Nagoya Protocol, supra note 127, art. 4(4).
162 WHO, PANDEMIC INFLUENZA PREPAREDNESS: SHARING OF INFLUENZA VIRUSES AND ACCESS TO
VACCINES AND OTHER BENEFITS (2011) [hereinafter PIP Framework].
163 WHO Secretariat, Implementation of the Nagoya Protocol and Pathogen Sharing: Public Health




of the treaty. The collection and use of genetic resources from the high seas are
governed by the U.N. Convention on the Law of the Sea (UNCLOS) and are
currently being negotiated, while access to resources from Antarctica is governed
by the Antarctic Treaty where sovereignty claims are currently in abeyance. 164
d. Genetic Sequence Data under the CBD and Nagoya Protocol
The term "genetic resources" under the CBD and Nagoya Protocol
refers to the physical materials but may also be broad enough to include genetic
sequence data derived from the physical resources themselves. Indeed, some
countries have chosen to interpret the term "genetic resources" to include data
and information associated with the physical resource.1 65 There is concern,
particularly in the PIP Framework forum at WHO, that not including data within
the definition of "genetic resources" may provide users with the opportunity to
circumvent ABS. However, making genetic sequence data subject to benefit-
sharing obligations conflicts with the open access ideals of scientific research,
where data is published in public databases for other researchers to access and
utilize. Many international organizations and research bodies have taken
positions with respect to whether "digital sequence information" and underlying
genetic resources are coterminous with respect to the CBD and Nagoya Protocol.
In Part Ell, we examine how four international research collaborations have
addressed this legal complexity.
e. ABS as an Opportunity for Better Collaborations
While informal transfers of biological samples still occur, such practices
are likely to decrease in frequency as researchers become aware of their
obligations under the CBD, Nagoya Protocol, and various domestic laws, and as
the transfer of genetic resources is further formalized. While many have viewed
ABS regulations as a barrier to research, and there is no doubt that it adds yet
another layer of bureaucracy at the research planning stage, it may also be framed
as an opportunity to include scientists in provider nations.1 66 This is particularly
important in developing countries that may not have the capacity to initiate their
own large-scale research projects, as the examples in Part I illustrate.
Cooperative research between industrialized nations and (often developing)
biodiverse countries can provide training opportunities and facilitate technology
transfer, giving developing countries the capacity to conduct future research of
their own and further the scientific endeavor as a whole.' 67 Furthermore, partners
in biodiverse nations have a great deal to contribute to collaborative ventures,
including specialized local knowledge, novel perspectives and ideas, and
assistance with navigating their country's domestic ABS regulations.
Collaborations with partners in nations that contribute genetic resources to the
164 See CHARLES LAWSON, REGULATING GENETIC RESOURCES: ACCESS AND BENEFIT SHARING IN
INTERNATIONAL LAW 26, 93 (2012).
165 See ARTI K. RAI & MARGO A. BAGLEY, THE NAGOYA PROTOCOL AND SYNTHETIC BIOLOGY
RESEARCH: A LOOK AT THE POTENTIAL IMPACTS 6 (Synthetic Biology Project ed., 2013).
166 Id. at 24.
1671 d. at 25.
2020]
THE YALE JOURNAL OF INTERNATIONAL LAW
project presents a win-win scenario for large-scale scientific projects. There are
already many examples of successful collaborations with substantial benefits
being shared, although these are predominantly non-monetary benefits in the
form of laboratory equipment and supplies, training, and so on.168
For large-scale biological research collaborations that intend to collect
and utilize genetic resources from multiple countries, obtaining PIC and
negotiating MAT can be a hugely burdensome process, even when the project
does not have commercial intent. In one description of a large-scale genetic
sequencing project still in the planning phases, 169 The Economist reported:
It is also an effort in danger of running into the Nagoya
[P]rotocol. Permission will have to be sought from every
government whose territory is sampled. That will be a
bureaucratic nightmare. Indeed, John Kress of the
Smithsonian, another of the [Project's] founders, says many
previous sequencing ventures have foundered on the rock of
such permission.1
70
The complexities of obtaining access from every government providing
genetic resources to large-scale biology projects is compounded when what
started out as non-commercial research is translated into a marketable end
product, in which case, there may be a requirement to renegotiate MAT.
The default mode of ABS as prescribed by the CBD and the Nagoya
Protocol is a bilateral agreement between the provider nation and the user of the
genetic resource. In the context of large-scale international research
collaborations, this would necessitate approaching every participant's NFP and
CNA to apply for permits and/or negotiate benefit-sharing terms. The Nagoya
Protocol does consider other ABS modalities, including multilateral benefit-
sharing arrangements which are particularly useful in situations with multiple
provider and user parties. In such situations, it may be more efficient to devise a
set of ABS conditions that are broadly compliant with both the CBD and Nagoya
Protocol that can be used as standard terms and conditions for collaborative
activities.
f. The Effect of the CBD and Nagoya on Historical Models of
Accessing Genetic Resources
' Perhaps the most celebrated was the agreement between the National Biodiversity Institute of Costa
Rica (INBio) and the United States pharmaceutical company Merck. See Hanne Svarstad, National
sovereignty and genetic resources, in BIODIPLOMACY: GENETIC RESoURCES AND INTERNATIONAL
RELATIONS 53-54 (Vicente Sdnchez & Calestous Juma eds., 1994).
69 This is a description of the Earth BioGenome Project which is covered in detail in the third case-
study, infra, Section III.D.3.
170 Sequencing the World: How to Map the DNA ofAll Known Plants and Animal Species on Earth, THE




As the above analyses illustrate, past models of cross-border access of
genetic resources are anachronistic as a practical matter, and, in many cases,
illegal. For example, if a researcher requests that colleagues in another country
transfer genetic resources across international borders without obtaining the PIC
of the provider nation's CNA, that transfer may amount to a circumvention or
even contravention of the provider country's domestic ABS laws. 171 In such
circumstances, it is likely the responsibility of the individual and/or organization
sending the samples to ensure that they have complied with their home country's
access laws. This does not necessarily protect the user of informally transferred
samples from any legal liability, as parties to the Nagoya Protocol are directed
to implement measures to ensure "that genetic resources utilized within its
jurisdiction have been accessed in accordance with ... the domestic [ABS]
legislation or regulatory requirements of the other Party.1 72 The enforcement
mechanisms, however, remain opaque and uncertain although reputational risk
remains important and can end a project effectively cancelling the social license
to operate. It is now imperative to formally establish the provenance of those
samples, demonstrate that PIC was obtained by an authorized provider and
outline the MAT for the use of those samples. Increasingly these kinds of
transfers will need to be accompanied by the Nagoya Protocol's Internationally
Recognized Certificates of Compliance that certify PIC and establish lawful
provenance.1 73 The collection (or sampling) of new genetic materials, specimens
or samples from the environment (i.e. in situ genetic resources not accessed
through type collections or ex situ repositories) may be subject to domestic ABS
regulations, especially if those materials are to be used outside of the originating
country. These rules apply as much to research scientists with non-commercial
intent as they do to commercial entities such as pharmaceutical or cosmetic
companies looking to create a marketable product or process from genetic
resources.
Access and benefit-sharing regulations have changed the way that some
research scientists from museums, biobanks, universities and government
research institutes collect and share samples. However, the perception that
genetic resources are in the public domain persists (according to the ideal of open
access) in the biological sciences and many researchers are still unaware of the
legal requirements surrounding the collection and use of genetic resources for
research purposes.1 74 As such, unofficial methods for obtaining specimens for
use in scientific research continue. 175 These practices are, however, disappearing,
171 It is worth noting here that because the CBD and Nagoya Protocol accept state sovereignty over
genetic resources, the ABS administrative and policy measures can apply to the transfer of genetic
resources across domestic borders as well as international borders. Users of genetic resources should be
aware that some countries have implemented sub-national ABS measures.
7' Nagoya Protocol, supra note 127, art.15(l).
171 Id. art.17.
174 Swen C. Renner et al., Import and Export ofBiological Samples from Tropical Countries -
Considerations and Guidelines for Research Teams, 12 ORGANISMS, DIVERSITY & EVOLUTION 81, 82
(2012).
"' See Claire Lajaunie & Calvin Wai-Loon Ho, Pathogens Collections, Biobanks and Related-Data in a
One Health Legal and Ethical Perspective, 145 PARASITOLOGY 688, 689 (2018) ("For these reasons,
most pathogens have been shared without written documentation on appropriate management and use,
or without having obtained formal approval from national authorities.").
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and users of genetic resources need to ensure that their research activities comply
with the relevant access laws of the provider countries.
3. The Ethics of Large Biogenomic Projects
Separately from the changing law governing international scientific research
collaborations in the life sciences, some lawyers, scientists, and human rights
advocates argue that there are important ethical considerations that may weigh
against large investments in large-scale biogenomic mapping projects not
oriented toward specific objectives for human health and welfare. These critics
argue that given the vulnerability of many poor populations in low- and middle-
income countries to infectious disease, malnutrition, and lack of access to
healthcare, costly investments in research should be re-directed to disease
surveillance, food security, and universal health coverage. In one recent opinion,
Professors Edward Holmes, Andrew Rambaut, and Kristian Andersen criticized
the Global Virome Project (see Part III A) as an imprudent investment given how
vulnerable populations may be most effectively protected against the next
pandemic. They argue that genomic surveys of animal viruses, while optimal for
advancing a general understanding of viral evolutions, are unlikely to predict the
next outbreak strain. 176 They write "influenza viruses [for example] have
circulated in horses since the 1950s and in dogs since the early 2000s... [t]hese
viruses have not emerged in human populations, and perhaps never will - for
unknown reasons." 177 Viruses evolve at a rate that may render substantial
investment too difficult to scale.'
78
Andersen, Holmes, and Rambaut instead advocate more intensive
monitoring of at-risk populations through detailed screening of people who are
exhibiting symptoms that cannot easily be diagnosed, using advanced
technologies to map "the human 'infectome' ."179 They argue that pandemics may
be prevented by training local clinicians and health-oriented NGOs, to spot
spillover events. Once an emerging outbreak virus had been identified, it would
be analyzed quickly to establish what type it is and the mechanisms driving its
transfer amongst species of hosts. Relevant data would be passed to key
stakeholders, from researchers and health workers on the ground to international
agencies such as the WHO, so long as the data can be shared without intruding
on patient privacy concerns and other ethical issues.'
80
Similarly, Keith Robison, a researcher with Warp Drive Bio, argued that
the Earth BioGenome Project would not lead to useful discoveries without
176 Edward C. Holmes, Andrew Rambaut & Kristian G. Andersen, Pandemics: Spend on Surveillance,
Not Prediction, 55 8 NATURE 180, 180 (2018) ("Broad genomic surveys of animal viruses will almost
certainly advance our understanding of virus diversity and evolution. In our view, they will be of little
practical value when it comes to understanding and mitigating the emergence of disease.").
... Id. at 181.
178 Id.




defined objectives.181 Better investments might be made, Robison argues, in
specific insights for classes of new pharmaceuticals, interpretive technologies
(rather than just sequencing), or scaling the project to specific species in order to
maximize geographic variation. 182 This may be especially true given the state of
sequencing technologies that would be used.
Large-scale biological projects that are not designed to test specific
hypotheses are often derided as fishing expeditions. These criticisms make sense
at first impression - it would seem that a dollar spent on basic research is a dollar
not spent on a specific, more actionable intervention that might improve human
welfare. Yet these projects make it clear that they bring with them technology
investments in places and institutions that need them, do so with both abstract
and practical objectives in mind, and have already accounted for scaling their
activities so that they do not represent chaotic, random sequencing of all life. If
designed properly, these fishing expeditions will not only catch some fish, they
can also equip others with the ability to continue fishing on their own.
While there remain loopholes through which some unethical or legally
suspect research may be undertaken, it is unlikely that large-scale international
projects will be tempted to exploit these loopholes anymore, or otherwise find
ways to avoid benefit-sharing obligations when collecting and utilizing the
genetic resources of other nations. Today, the risk is such that the project could
be shut down owing to the Nagoya Protocol's compliance mechanisms or simply
to public outcry:
Most rational researchers and industry will inevitably be
seeking to avoid the public relations issues of having a project
identified as non-compliant under the [ABS Clearing House
Mechanism] and then run the risk of having their research
called "biopiracy." 183
HI. GLOBAL BIOGENOMIC PROJECTS: CAPACITY BUILDING AND
BENEFIT SHARING
The law and ethics of these emerging scientific research endeavors are
complex and intertwine overlapping currents in international environmental law,
public health preparedness, food security, and heated discussions about global
wealth disparities. In this Part, we analyze four large biogenomic studies (there
are dozens of smaller ones, many of which do not implicate the legal and ethical
questions presented here) in order to understand whether these projects aim to
comply with national and international access and benefit sharing law and
contribute meaningfully to the building of research, public health, and
agricultural capacity in the countries in which they operate or whether, as critics
allege, they are largely oriented toward abstract research objectives unlikely to
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translate into scientifically valuable outcomes or improvements in low- and
middle-income countries. Each will provide some insights as to how to approach
ABS rules and regulations depending on the size and overarching intent of the
project. These case studies will detail the aims of the projects, the types of genetic
resources that the projects seek to obtain and how they go about doing so. Each
of the case studies will conclude by examining the capacity-building and ABS
lessons and implications for future large-scale collaborative biological projects.
These projects are at different stages of implementation and address in
different ways and at different levels of accomplishment the challenge of
reconciling access to biological resources, the generation of scientific results and
the equitable management of the benefits arising from their utilization. As the
analyses demonstrate, these projects emphasize the importance of discovery and
characterization of biological organisms as pathways both to scientific progress
and collaboration within and between scientific communities and towards future
research, development, and innovation.
A. The Global Virome Project
1. Project Description and Aims
The "Global Virome Project" (GVP) was launched at a meeting in Bellagio,
Italy, in 2016 and is currently at a stage of institutional development and
planning.1 84 The GVP is led by a group of scientists and researchers coming from
governmental and scientific institutions as well as non-governmental
organizations and academia. The leadership of the initiative comes from the USA
with the support of scientists and public authorities in other key countries such
as China, Brazil, and Thailand.
The rationale of the GVP starts from the widely accepted consideration that
the world is chronically unprepared for outbreaks of emerging and re-emerging
diseases, particularly those with pandemic potential, and that most of the high-
risk pathogens that have caused outbreaks in the recent past - predominantly
viruses - are of animal origin.1 85 The risk of zoonotic spillover is largely a
function of human encroachment into wildlife habitats, in particular by
increasing contacts with species that have proven to be reservoirs of viruses such
as bats, primates, and rodents. 186 The transboundary consequences of such
spillovers are then magnified by growing population density and high levels of
mobility across countries. That this applies to countries at all levels of
184 Bellagio Initiative on the Global Virome Project, GLOBAL VIROME PROJECT (2016),
https://staticI .squarespace.corn/static/581a4a856b8f5bc98311 fbO3/t/582120e4ffT7c5080cc611 fd6/14785
66120350/GVP+Bellagio+Initiative.pdf (last visited Nov. 13, 2019).
" See Laurel Hamers, Global Virome Project is Hunting for More than 1 Million Unknown Viruses,
SC. NEWS (Feb. 22, 2018), https://www.sciencenews.org/article/global-virome-project-unknown-virus-
outbreak.
..
6 See Robin MeKie, Scientists Aim to Stop the Devastation of Zika-like Pandemics, THE GuARDIAN




development and social mobility is proven by the quick spread of the 2014-2016
Ebola outbreak across Guinea, Liberia, and Sierra Leone, and further on to other
African countries such as Nigeria.187 The predictable intensification and
acceleration of international outbreaks of zoonotic diseases in the future point to
the inadequacy of the current reactive approach to prevention and control,
whereby states and international organizations such as WHO rush to identify
pathogens only after the start of an outbreak. 188 This approach inevitably causes
delays in characterizing the pathogens, managing risk and clinical interventions,
and laying the ground for the development of medical countermeasures such as
diagnostics, vaccines, and antivirals. It should be added that public health
responses generally target one pathogen at a time, thus ignoring possible
similarities among viruses belonging to the same family for the purposes of
developing more generally effective countermeasures.
Available data and statistical models have suggested an alternative approach
that is currently being developed through the GVP, building on a concurrent
multi-team project on emerging pandemic threats led by the University of
California-Davis. 189 It is reported that "[a]round 263 viruses from 25 viral
families are known to infect humans;" an extrapolation based on historical
patterns leads to the predictable presence of more than 1.6 million viruses in
mammalian and bird hosts alone, of which between 631,000 and 827,000 may
have zoonotic potential. 190 In other words, more than 99% of animal viruses
remain undiscovered, many of them with the potential of becoming the source
of future zoonotic outbreaks.
The GVP aims at reversing the reactive approach described above through
the establishment of a "global atlas of zoonotic viruses."191 In synthesis, the GVP
constitutes a 10-year global scientific initiative to proactively identify a high
proportion of animal viruses in a number of particularly relevatit hosts (bats,
rodents, primates, and aquatic birds) in countries rich with those species and
characterize those with spillover potential. By both scaling up sampling and
sequencing technology (in particular in developing countries) as well as
establishing a global network of scientists from various disciplines, the GVP's
ultimate objective is to build an unprecedented database of viruses in their
ecological context. As in the case studies reviewed in the previous section, the
ultimate product of GVP would be an open-access database of genetic sequences
beside biobanks containing actual samples. The aforementioned PREDICT
project has offered a proof of concept by achieving the identification of about
187 See Bryan Walsh, The World is Not Ready for the Next Pandemic, TIME (May 4, 2017),
http://time.com/4766624/next-global-security/.
188 See id.
189 PREDICT is implemented by a consortium of institutions led by the School of Veterinary Medicine
of the University of California at Davis. See Global Virome Project, UC DAVIS VET. MED.,
https://ohi.vetmed.ucdavis.edu/programs-projects/global-virome-project (last visited Nov. 13, 2019).
'9 Dennis Carroll et al., The Global Virome Project, 359 Sci. 872, 872 (2018).
191 Dennis Carroll et al., Building a Global Atlas of Zoonotic Viruses, 96 BULL. WHO 292, 292 (2018).
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1,000 new viruses since its inception in 2009.192 The GVP aims to scale up those
achievements, focusing on large-scale sampling and viral discovery rather than
on capacity building and epidemiological analysis, which is instead the focus of
PREDICT.
2. Capacity Building, Access, and Benefit Sharing
The goal of the GVP is to enhance current international surveillance
programs by sampling the aforementioned animal species, sequencing viral
families, and creating an atlas for researchers to understand how those viruses
may spill over to human hosts. This would facilitate targeted surveillance and
prevention, as well as inform necessary behavioral changes to increase protection
of human populations. It would also shorten the time gap between outbreak
detection and identification of the virus. The primary legacy of the GVP in
scientific terms would be both sample biobanks and databases of sequence
information as well as metadata. Available information could be processed
through a "big data" approach to identify patterns and similarities among viruses
and facilitate predictions about their zoonotic potentials. 193 Furthermore, the
second main legacy would be increased laboratory, sampling, and surveillance
capacity in participating developing countries (since most of the targeted animal
species live in tropical and equatorial regions). The PREDICT project alone
trained approximately 5,000 individuals in 30 countries in disease detection and
increased the sequencing capacity of over 60 labs to undertake a range of
research tasks.1 94
As represented in recent publications, there are two benefits to the project.
The first is that the availability of samples and sequences of pathogens causing
outbreaks will save precious time and resources and enable the quicker
production of diagnostics and medicines. The second benefit is that the
sequencing and characterization of a high number of viruses belonging to the
same family could facilitate the development of broad-spectrum vaccines that
could be effective against a number of viruses sharing similar genetic
characteristics. The GVP could play a complementary role to public-private
partnerships that support riskier investments in the development of new
medicines or vaccines by providing access to the necessary samples or
192 See Donald G. McNeil, Jr., Scientists Were Hunting for the Next Ebola. Now the U.S. has Cut Off
Their Funding, N.Y. TIMES (Oct. 25, 2019), https://www.nytimes.com/2019/10/25/health/predict-usaid-
viruses.html.
"' See Carroll et al., The Global Virome Project, supra note 190, at 872 ("We estimate, from analysis of
recent viral discovery data, that -1.67 million yet-to-be-discovered viral species from key zoonotic viral
families exist in mammal and bird hosts-tbe most important reservoirs for viral zoonoses. By
analyzing all known viral-host relationships, the history of viral zoonoses, and patterns of viral
emergence, we can reasonably expect that between 631,000 and 827,000 of these unknown viruses have
zoonotic potential. We have no readily available technological countermeasures to these as-yet-
undiscovered viruses. Furthermore, the rate of zoonotic viral spillover into people is accelerating,
mirroring the expansion of our global footprint and travel networks, leading to a nonlinear rise in
pandemic risk and an exponential growth in their economic impacts.") (internal citations removed).
194 See McNeil, Jr., supra note 192.
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sequences, including potentially the recently established Coalition for Epidemic
Preparedness Innovations (CEPI).' 95
3. Implications for Large-Scale Biological Projects
Indeed, the structure of the GVP as articulated in a number of presentations
and publications is oriented not only toward facilitating access and benefit
sharing, but also toward building capacity tailored to each participant country's
particular circumstances. The planned structure of the GVP is a
decentralized/federal one where activities are managed independently at the
national level while a central hub will provide coordinating and normative
functions, in particular through the adoption of agreed protocols on operating
procedures and technical requirements. 196
From a political perspective, the GVP may attract the attention of key
governments and move beyond a purely scientific project, for example by
becoming an intergovernmental program not dissimilar from the WHO's
systems for pandemic influenza preparedness. To the extent that the international
access component of the GVP falls under the Nagoya Protocol, participating
entities will have to comply with the multiple legal requirements of the Protocol,
(e.g. in terms of prior informed consent and mutually agreed terms for access
and benefit-sharing).
From the beginning, the GVP has committed to compliance with the Nagoya
Protocol, declaring that:
The GVP's field operations are designed to contribute to host
countries' systems and capacities, providing benefits including,
but not limited to, promoting research collaboration; sharing of
data and research results; and building in-country research
capacity. Further, the Global Virome Project will work in
partnership with governments where they determine that a
specialized international instrument (Article 4.4 of the Nagoya
Protocol) or special considerations (Article 8 of the Nagoya
Protocol) may best guide the implementation of the CBD's and
the Nagoya Protocol's access and benefit sharing principles.' 97
1 See Eni Togami et al., The Global Virome Project, BULL. WHO 4-5 (2018),
https://www.who.int/bulletin/online-first/BLT.17.205005.pdf ("The recently launched Coalition for
Epidemic Preparedness Innovations [CEPI] represents a critical step to address known viral threats, such
as the Middle East respiratory syndrome coronavirus, Lassa fever and Nipah virus, for which vaccine or
countermeasure development is challenging. The Virome project aims to complement the coalitions'
innovations by characterizing the size, structure and composition of the pool of unknown viruses related
to the viral targets on which the coalition is focused.") (internal citations removed).
.96 See Carroll et al., Building a Global Atlas of Zoonotic Viruses, supra note 191, at 292 ("The Global
Virome Project will operate as a federation of national and regional projects led by in-country
researchers, who are in turn connected to a global hub that provides standardized protocols and monitors
progress.").
"' ELSI Working Group, GVP Statement on Compliance with the Nagoya Protocol (on file with
author).
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The GVP's leadership is currently considering options with regard to both
biobanks to store samples and, more importantly, databases to store and regulate
access to sequences and metadata. A number of such data repositories are already
in operation, such as GISAID 198 in Germany and GenBank 199 in the USA; they
could either provide possible models to manage new national or multilateral
databases, or even to host GVP-origin genetic sequences.
Economists at the EcoHealthAlliance have estimated that:
Having a baseline of identified viral sequences would lead to earlier
detection and quicker response times, lowering both epidemic frequency and
impact. These improvements would not have an immediate impact, but benefits
would accumulate throughout and beyond the lifespan of the GVP. For our
calculations, we assume that these benefits collectively lead to an average of 10%
in savings from damages in all events in the next 30 years ($290-480 billion). As
such, a $1.2 billion Global Virome Project would return over $200 dollars in
savings for each dollar invested. As the EcoHealth Alliance notes:
Even if the GVP only reduces the likelihood and impact of
EIDs by 10%, this project would generate large returns on
investment . . . [t]he premature loss of lives and economic
shocks account for the largest proportion of economic damages
from ED events. A $120 million annual budget for a 10-year
Global Virome Project is an investment that could produce
exceptionally high returns.
211
Much of this benefit will occur through the catalysation of "technological
advances in risk assessment, diagnostics and countermeasures" in developing
countries.
20 1
B. Earth Microbiome Project (EMP)
1. Project Description and Aims:
The Earth Microbiome Project (EMP) was launched in August 2010 and is
an ongoing effort to genetically sequence "the uncultured microbial diversity of
this planet., 2 2 The term "microbiome" refers to all microorganisms (bacteria,
archaea and single-celled eukaryotes) that inhabit a particular environment or
larger organism. The EMP aims to characterize the "bacterial, archaeal, and
19' Home Page, GISAID, https://www.gisaid.org/ (last visited Nov. 13, 2019).
199 GenBank Overview, NCBI, https://www.ncbi.nlm.nih.gov/genbank (last visited Nov. 13, 2019).
20O EcOHEALTHALLIANCE PREDICT MODELING & ANALYTICS TEAM, GLOBAL COSTS OF EMERGING
INFECTIOUS DISEASES: AN ECONOMIC CASE FOR THE GLOBAL VIROME PROJECT 2 (2018),
http://livescience.ecohealthaliance.org/predict/reports/2018-04-16-edi-economic-case-for-the-GVP.pdf.
201 Togami et al., supra note 195, at 5.




eukaryotic microbial diversity" that comprise the Earth's entire microbiome. 20 3
By way of explanation, the microbiome of different species of trees will exhibit
high levels of variability, even if they grow side by side in the same forest. The
microbiome of a lake will vary with temperature and weather events, meaning
that different species of microbes will thrive as the environmental conditions
change. Therefore, even with hundreds of thousands of samples the data
generated by the EMP will only represent a minute proportion of the Earth's
actual microbiome.
The EMP has already resulted in a database of genetic sequences that is
incremental and comparable. More sequences can be added to the database over
time so that researchers have access to as much of the known genetic sequence
data from around the world as possible. Until the advent of high-throughput
genetic sequencing technologies, a lot of microbial species were not
"discoverable" by scientists because most microorganisms are not readily
culturable. That is, they cannot be grown or amplified in the laboratory for
further study. Looking for the genetic material contained in environmental
samples ensures that researchers are capturing genetic sequences from all
microbes, not just those that can be cultured. So far, the majority of the sequences
that have been generated by the EMP are of ribosomal ribonucleic acid (rRNA)
molecules. Ribosomes are present in all cells and are sufficient markers of
genetic variability across species, so rRNA is often used in taxonomic studies to
construct phylogenies, a type of evolutionary family tree that groups organisms
based on genetic relatedness.
20 4
The EMT was founded and led by microbial ecologist Jack Gilbert of
Argonne National Laboratory, microbiologist Rob Knight of the University of
California, San Diego, and biologist Janet Jansson of Pacific Northwest National
Laboratory. The Project initially relied on crowdsourcing to obtain samples.
They put out the call to microbial ecologists from around the world to send in
environmental samples to be analyzed by the laboratories of the three EMP
cofounders in the United States.205 In a 2011 blog post requesting sample
contributions, one of the EMP Steering Committee members, Jonathan Eisen of
the University of California, stated that "[e]xamples of things that could be useful
include soil samples from a transect along the equator, filtered water from all
lakes in Minnesota, deep sea sediment cores, filtered air from giant dust storms,
microbial mats from hypersaline ponds, and so on."20 6
203 Luke R. Thompson et al., A Communal Catalogue Reveals Earth 's Multiscale Microbial Diversity,
551 NATURE 457, 458 (2017).
2 4 d. There is, of course, an ongoing controversy about the appropriate and suitable taxonomic
frameworks; see, e.g., Charles Lawson, Taxonomic Conceptions ofAlgae, Animals, Fungi and Plants in
Granting Intellectual Property Privileges, 19 GRIFFITH L. REv. 472 (2010).
2
os Luke R. Thompson, Wrangling the Microbiomes of Earth, NATURE MICROBIOLOGY COMMUNITY
(Nov. 1, 2017), https://naturemicrobiologycommunity.nature.com/users/69805-luke-
thompson/posts/22169-wrangling-the-microbiomes-of-earth; Laboratories, EARTH MICROBIOME
PROJECT, http://www.earthmicrobiome.org/people/laboratories (last visited Nov. 13, 2019).
206 Jonathan A. Eisen, Wanted. Sample Collections for the Earth Microbiome Project (EMP); Help
Make an Open Field Guide to the Microbes, PHYLOGENOMICS: THE TREE OF LIFE BLOG (Apr. 27,
2011), https://phylogenomics.blogspot.com/2011/04/wanted-sample-collections-for-earth.html.
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In the first phases of the EMP, the environmental samples were sent to
one of the EMP wet labs which extracted the nucleic acids and generated the
genetic sequence data. The genetic sequence data was published on the EMP's
online database and is openly accessible for anyone to explore. 20 7 This meant
that researchers from around the world could have their existing samples
genetically sequenced for just the price of shipping them to the EMP labs in the
United States. Researchers were then free to analyze the genetic sequence data
of not only the samples they provided, but the samples of all other contributors.
In the current phases of the EMP, researchers can contribute data
directly to the database if they follow the EMP's standardized protocols for
sample and metadata collection, DNA extraction, and genetic sequencing.
Creating standardized procedures ensures the integrity of the data despite being
contributed by disparate laboratories. It can reduce bias and may allow for more
accurate comparisons with the rest of the EMP data. 08 Some of the data analysis
is being conducted by members of the EMP working group, but the EMP also
encourages researchers from around the world to interrogate the EMP genetic
sequence database, conduct their own analytics and publish the findings. The
only stipulation is that the EMP be acknowledged in the Methods and
Acknowledgements sections of the publication and that the original EMP paper
be cited.20 9 This communal approach to data generation and analysis has already
led to around 60 peer reviewed studies in academic journals.210 Because the EMP
is building its database from constituent scientific projects that are testing their
own individual hypotheses, the EMP has managed to avoid derision as a "fishing
expedition", a common insult directed at large scale projects that collect samples
and data without a clearly defined plan for their use.
The results of the EM have been promising, and the database of microbial
genetic sequences continues to expand. In their 2017 meta-analysis of 97
independent studies that contributed to and used EMP data,211 the EMP team
reported that more than 2.2 billion microbial genetic sequences had been
generated from 27,751 environmental samples.21 2 This included the "a total of
307,572 unique sequences", that is, genetic sequences that were not previously
known to science. 213 As expected, this represents only a minute fraction of the
Earth's actual microbiome, but it is a good starting point. The main contribution
of this large-scale project appears to be the promulgation of standardized
research methods that have been accepted and used by those contributing
207 See Data and Code, EARTH MICROBIOME PROJECT, http://www.earthmicrobiome.org/data-and-code/
(last visited Nov. 13, 2019).
201 Jack A. Gilbert & Folker Meyer, Modeling the Earth Microbiome, 7 MICROBE 64, 68 (2012).
209 Home Page, EARTH MICROBIOME PROJECT, http://www.earthmicrobiome.org/ [hereinafter Earth
Microbiome Home Page] (last visited Nov. 13, 2019).210 See Publications, EARTH MICROBIOME PROJECT, http://www.earthmicrobiome.org/publications/ (last
visited Nov. 13, 2019).
211 See Luke R. Thompson et al., supra note 202, at 458 (Supplementary Table 1).
212 Id. at 458 (sequence reads were between "90-151 base pairs.").
2131 d. at 459.
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samples and data to the EM and are likely to be used as communal standards
for a while to come.
2. Capacity Building, Access and Benefit Sharing
Looking for diverse species of microorganisms within diverse
environmental samples including soil, water, feces, sponges and corals, meant
that the EMP team needed a broad (but not necessarily systematic) sampling
strategy. In the initial phases of the project, "[t]he EMP solicited the global
scientific community for environmental samples and associated metadata
spanning diverse environments and capturing spatial, temporal, and/or
physicochemical covariation.'24 There were some doubts as to how successful
the crowdsourcing strategy would be as it was assumed that researchers would
be reluctant to hand over their samples for testing.215 While there is usually little
financial value in the samples for the research teams that collected them, their
value is wrapped up in the physical (and sometimes bureaucratic) efforts that it
took to obtain the samples in the first place and the ongoing costs of storage.
The crowdsourcing of samples "from researchers around the world" was
deemed "a success" as early as 2014,216 and by May 2018, the EMP was no
longer accepting sample contributions from scientists as they had reportedly
reached processing capacity.2 17 According to one report, "[m]ore than 500
researchers sent in samples, from 43 countries across the world. The team soon
had thousands of samples-all neatly packed into about 25 freezers across the
three founders' laboratories". 2 18 It could be argued that the generosity of donors
to the EMP demonstrates that the Mertonian norm of communality is still alive
and well in the sciences, despite the constant pressures to commercialize
academic outputs. 2 19
Crowdsourcing samples allowed the EMP to amass specimens from 43
different countries, representing all seven continents. 220 The EMP was founded
in 2010, the same year that the Nagoya Protocol was adopted by the Conference
214 Id. at 458.
215 Gilbert et al., supra note 202, at 1.
2 16 Id,
27 Earth Microbiome Home Page, supra note 209. ("The Earth Microbiome Project is a systematic
attempt to characterize global microbial taxonomic and functional diversity for the benefit of the planet
and humankind.").
218 Katarina Zimmer, Researchers Catalog Earth's Microbiome, THE SCIENTIST (Feb. 1, 2018),
https://www.the-scientist.com/notebook/researchers-catalog-earths-microbiome-30120.
219 Note that Merton originally used the term "communism" not "communality" which has been used
here. Since the publication of Merton's famous essay in 1942, the word "communism" has come to take
on additional significance and meaning that was not in keeping with the way Merton used the term. The
other three scientific norms that Merton identifies as "the ethos of science" are universalism,
disinterestedness and organized skepticism. See ROBERT K. MERTON, The Normative Structure of
Science, in THE SOCIOLOGY OF SCIENCE: THEORETICAL AND EMPIRICAL INVESTIGATIONS 268-278
(Robert K. Merton & Norman W. Storer eds., 1973).
220 Luke R. Thompson et al., supra note 203, at 458 (2017).
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of the Parties to the CBD.22 1 This means that there could be up to 43 different
sets of ABS regulations that may apply to the samples that were being sent to the
EMP laboratories in the United States. In the 2010 report from the first EMP
meeting on sample selection and acquisition, the authors note that:
The bottlenecks for this project will likely not be sequencing,
but rather identifying projects that can provide samples,
determining whether the samples adhere to strict requirements
for associated metadata that support integration efforts, and the
infrastructure, protocol and legal implications of such an
endeavor.2
22
And the same report goes on to note that:
Obtaining samples from outside of the US would be the most
significant problem, licenses and permits would be required,
and the countries from which samples were sent would neea to
agree to sequencing and downstream analysis to prevent
litigation. Rick Stevens [of Argonne National Laboratory]
suggested that the EMP could potentially ship a sequencer into
the country and this would prevent shipping costs and permits
for the physical samples or DNA. Rob Knight suggested that
one possible solution would be to have visitors come and
extract samples at an EMP affiliated Laboratory.
2 23
The report therefore indicates that the organizers of the EMP were aware
that there were indeed legal considerations for the transnational movement of
samples. However, it is not clear if the awareness extended only to biosafety and
import/export controls, or whether it included ABS and the associated
requirements of obtaining PIC and establishing MAT before utilizing other
nations' sovereign genetic resources. The authors of the report state the
requirement for "licenses and permits," although this could be for import/export
controls (such as international agreed sanitary laws), not necessarily access
permits. However, one thing that does seem to suggest an awareness of ABS is
the suggestion to "ship a sequencer" into the host country as a cost-effective
alternative to paying for "shipping costs" of samples "and permits. '224 This
would constitute a form of an annexed research site (described in Part II). It
should be noted, however, that many countries may now wish to regulate access
to the genetic sequence data in the same way that they regulate access to the
samples themselves.
2 1 Id. at 457.
222 Jack A Gilbert et al., The Earth Microbiome Project: Meeting Report of the 1st EMP Meeting on




3. Implications for Large-Scale Biological Projects:
The crowdsourcing approach used by EMP is relevant because it
circumvents the need to collect samples anew. The coordinating researchers may
have been working on the assumption that either these historical samples are not
within the remit of the CBD and considered common heritage,225 that they are
the lawful property of the scientists (or their institutions) that collected them, or
that all of the regulatory hurdles have been cleared at the original point of access.
The report from the first "EMP meeting on sample selection and acquisition"
held in October 2010 indicated that the discussion was premised on the fact that
individual scientists or research teams (teams of scientists that work together,
usually with a principal investigator or lab head, are often referred to in the
scientific community as "labs") owned the samples in their possession. The
biggest and "possibly insurmountable" problem discussed was actually the "ego"
of scientists not wanting to share their samples or data or to be beaten to
publication by other researchers with access to their samples or data.2 26 The
report indicated that the meeting participants were aware of the potential for
commercial outcomes.227 Furthermore, there seemed to be some hesitance about
receiving samples from outside the U.S., 22 8 but the reasons for this are unclear
in the report. In terms of the samples sourced from other researchers, there may
be an assumption that the samples were initially collected in compliance with
ABS regulations. This leaves compliance up to the contributors of samples to the
larger EMP. However, this does not necessarily indemnify the EMP-affiliated
laboratories that are utilizing the shipped samples to generate sequence data from
ABS obligations unless they can be sure that as third-party users, they are not
subject to any viral use clauses stemming from the original ABS contract.
There is an awareness expressed by the EMP meeting attendees that there
may be a requirement to obtain a permit when receiving samples from outside
the U.S., but it is not clear if that permit is related to any ABS obligations. It
could be referring to import/export permits as opposed to access permits. Indeed,
there is no sense that there is an awareness of any rights to the samples other than
those that are attributed (by the meeting attendees) to the scientists that collected
and are storing them. This points to lack of awareness of .the principles of
resource sovereignty and ABS contained in the CBD and Nagoya Protocol. This
is understandable given the timing of the project. The initial meetings (and this
sample acquisition meeting) were held in 2010, before the Nagoya Protocol was
adopted. There was (and still is) limited awareness of these issues and how
25 This may indeed be the case if the crowd-sourced samples were collected prior to the entry into force
of the CBD on December 29, 1993.
226 Gilbert et al., supra note 222, at 252-3.
227 Id. at 250.
22" Noting here that the U.S. is not party to the CBD, and thus cannot be a party to the Nagoya Protocol.
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sovereign authority over genetic resources might impact sampling practices or
the use of those genetic resources.229
A team of Brazilian researchers detailed the benefits of locally-led
microbiome projects as strengthening conservation efforts, building
infrastructure to protect national genetic heritage, training new scientists and
researchers, increasing the use of beneficial organisms, suppressing pathogenic
microorganisms in plants and humans and building the technological base of
the country.
230
C. Micro B3 (Biodiversity, Bioinformatics and Biotechnology)
1. Project Description andAims:
The Marine Microbial Biodiversity, Bioinformatics, and Biotechnology
project, shortened to the Micro B3 project, was a European venture that operated
from January 1, 2012 until December 31, 2015.231 The Micro B3 project was not
itself a bioprospecting project. Rather, it was an interdisciplinary effort to reduce
technical and legal barriers for smaller marine bioprospecting projects and to
standardize and integrate marine microbiological datasets for maximum utility
for both non-commercial scientists and commercial researchers. The advent of
high-throughput sequencing technologies has resulted in vast amounts of data,
and the Micro B3 project was largely a response to the fact that "the processing
and analysis of the data mostly outcompetes the bioinformatic capacities of many
researcher groups and institutes in the marine field., 232 Thus, the Micro B3
project would facilitate the characterization of "marine viral, bacterial, archaeal
and protists genomes and metagenomes" 233 "by providing access to, and by
integrating genomic, oceanographic and Earth observation databases into, one
Micro B3 Information System (MB3-IS), based on global standards for sampling
and data processing." 234
The Micro B3 project was, at its core, about building bioinformatics capacity
in Europe, but one of its key features was Ocean Sampling Day (OSD).235 Held
on June 21, 2014 and repeated in 2015, the OSD was "a simultaneous global
mega-sequencing campaign aiming to generate the largest standardized
229 For a discussion on the limited awareness of ABS in botanic gardens even after the introduction of
the Nagoya Protocol, see Kate Davis et al., An Access and Benefit-Sharing Awareness Survey for
Botanic Gardens: Are They Prepared for the Nagoya Protocol?, 98 S. AFR. J. BOTANY 148 (2015).
230 Victor S. Pylro et al., A Step Forward to Empower Global Microbiome Research Through Local
Leadership, 24 TRENDS IN MICROBIOLOGY 767-70 (2016).
231 The Micro B3 Project homepage, supra note 76.
232 Id.
233 Id.
234 Micro B3, MICROBIAL BIODIVERSITY, BIOINFORMATICS, BIOTECHNOLOGY 4 (2012),
https://www.microb3.eu/sites/default/files/media-materia/printed materia/MtCROB3-Brochure-Lowr
es 25 01 2013.pdf [hereinafter Micro B3 brochure].
233 Sarah J. Bourlat et al, Genomics in Marine Monitoring: New Opportunities for Assessing Marine
Health Status, 74 MARINE POLLUTION BULL. 19, 25 (2013).
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microbial data set in a single day., 2 3 6 The water sampling was conducted by
contributors at 191 sites around the world using Micro B3 standardized
procedures, 237 and the microbial samples were sent to a laboratory in Germany
for DNA analysis. This was essentially a proof of concept for the Micro B3
Information System (through which the data was processed) and a test of the best
practices protocols that had been developed by the project.238 The 2014 OSD
resulted in the collection and characterization of "155 16S/18S rRNA amplicon
data sets, 150 metagenomes, and a rich set of environmental metadata,"
providing "the largest standardized data set on marine microbes taken on a single
day 239 and "more than 80 peer-reviewed publications. 2 4 °
2. Capacity Building, Access and Benefit Sharing
The Micro B3 project was attuned to the commercial potential of marine
microbial resources, stating that they provide "excellent opportunities for
bioprospecting for novel enzymes of industrial interest and for metabolic
products.",24 1 Thus, from the outset, the project focused on issues of ABS and the
creation of model ABS agreements that would suit both non-commercial (public)
and commercial (private) stakeholders. The MicroB3 project description notes:
Since Micro B3 is likely to bring about the discovery of new
biotechnological applications for marine microbial data, there
are complex issues of intellectual property involved,
particularly given that much of the data gathered originates in
exclusive economic zones or areas of ocean completely beyond
any national jurisdiction. 242
The Micro B3 project therefore makes for a useful case study into the
sorts of ABS policies that can be applied to microbial sample collection, data
generation and information sharing.
The Micro B3 project was headed by Dr. Frank Oliver G15ckner, Head
of Microbial Genomics and Bioinformatics Research Group at the Max Planck
Institute and Professor of Bioinformatics at Jacobs University, Germany. 243 It
236 Anna Kopf et al., The Ocean Sampling Day Consortium, 4 GIGASCIENCE 1, 2 (2015).
237 Ocean Sampling Day, MICRO B3 (2015), https://www.microb3.eu/osd.html.
238 Micro B3 brochure, supra note 234, at 3.
239 Kopf, supra note 236, at 1.
240 Reportfrom the Micro B3 Final Conference 2-5 November 2015, MARINE BIOTECH ERA-NET (Nov.
17, 2015), http://www.marinebiotech.eu/news-and-events/era-news/report-icro-b3-final-conference-2-
5-november-2015.
241 Background, MICRO B3, https://www.microb3.eu/about.html (last visited Nov. 13, 2019) (emphasis
omitted).
242 Micro B3 brochure, supra note 234, at 3; see also Rildiger Wolffurn & Nele Matz, The Interplay of
the United Nations Convention on the Law of the Sea and the Convention on Biological Diversity, 4
MAX PLANCK Y.B. OF U.N. L. 445, 462 (2000)
https://www.mpil.de/files/pdf2/mpunybwolfrum matz_4.pdf (The "exclusive economic zones" of
nation states are within the remit of the CBD).
243 Micro B3 brochure, supra note 234, at 2.
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built on preexisting European projects and collaborations and worked alongside
the European Marine Biological Resource Centre and the European Life
Sciences Infrastructure for Biological Information. 244 The Micro B3 project was
funded by the European Union's (EU) Seventh Framework Programme (7FP), a
research and innovation funding scheme that ran from 2007-2013 .245 The Micro
B3 was arranged as an "interdisciplinary consortium of 32 academic and
industrial partners ' 246 based in Europe, and the project team included specialists
in bioinformatics, data modelling, intellectual property and experts from biotech
companies. 247
As part of the standardized protocols developed by the Micro B3 project
and used in the Ocean Sampling Day, the Micro B3 team developed policies for
ABS, material transfer, and data transfer agreements. The acknowledgement that
marine microbial bioprospecting could ultimately result in marketable products
meant that appropriate attribution of intellectual property and compliance with
the Nagoya Protocol were key considerations from the outset of the Micro B3
project.2 48 The project was divided into nine 'Work Packages,' one of which was
Work Package 8: "Intellectual Property (IP) Management for Marine
Bioprospecting."249 The aims of the IP Work Package were outlined on the
projects website:
(a) efficient dissemination of materials, software, data and
published results to a wide range of science communities and
other users / stakeholders (b) appropriate IP protection and
management (including patent, copyright and trade secrecy
issues) (c) measures for compliance with the provisions of the
Nagoya Protocol on access and benefit sharing with a view to
involve resource states in the R&D activities and contribute to
the protection and preservation of the marine biodiversity. 5 °
The Micro B3 project differentiates between "pre-competitive
utilization/research" of marine microbial genetic resources, and use or research
for "competitive research and for hybrid situations", recognizing that the Micro
B3 project will have the potential to generate both.251 The pre-competitive
research is that which is conducted for furthering science generally, the results
of which will be in the public domain. The latter refers to any proprietary
244 Id.
245 Understanding the Seventh Framework Programme, EUR COMMISSION.,
https://ec.europa.eu/research/fp7/index-en.cfm?pg=understanding (last updated Aug. 25, 2015).
246 The Micro B3 Project homepage, supra note 76.
247 Micro B3 brochure, supra note 234.
248 Id. at 3.
249 Work Packages, MICRO B3, https://www.microb3.eu/work-packages.html (last visited Nov. 13,
2019).
250 Intellectual Property (7P) Management for Marine Bioprospecting, MICRO B3,





research and development which will be eligible for protection under the
standard suite of intellectual property protections.
The project uses data gleaned from microbial genetic resources
collected in both the sovereign oceanic areas belonging to coastal countries as
vell as areas beyond national jurisdiction (ABNJ) on the high seas.25 2 For those
samples collected on the high seas, the United Nations' Convention on the Law
of the Seas (UNCLOS, 1982) applies.253 This treaty treats the "natural resources"
on the high seas as a global commons, in part regulated by the International
Seabed Authority. The commentary to the Micro B3 model agreement explains:
[T]he access to and the utilization of genetic resources taken
from the ABNJ is free (Articles 87, 256 UNCLOS), but limited
by the respect of the conditions laid down by UNCLOS, and by
the respect of the interests of other States and of the right under
the convention with respect to activities in the Area (Article
87). No access agreement needs to be, nor can be, concluded.254
The majority of the sampling activity associated with the Micro B3
project and the Ocean Sampling Days occurred "within internal waters, the
territorial sea, and the exclusive economic zone of coastal states" and in these
cases, the CBD's provisions on accessing genetic resources applied.255 The
Micro B3 project therefore adopted an approach "based on the Nagoya Protocol"
which entered into force in October, 2014, while the project was running and
aimed "to produce model [ABS] contracts and good practice standards
specifically tailored to the marine field. '256 The final model agreement is
available online; 257 so, too, is an insightful discussion detailing the objectives of,
and the conflicts between, the regulatory frameworks that the model agreement
is based upon.258 The model agreement not only serves as the recommended
contract for Micro B3 partners, but the authors of the agreement have noted that
it "can also be used for other projects, such as those on genetic resources other
than marine microorganisms", and would probably require only "minor changes
in the text" of the template.259
22 Micro B3 Brochure, supra note 234, at 3.
253 For a discussion on the jurisdiction of UNCLOS and its application to living and non-living "natural
resources," see Lawson, supra note 164, at 93.
254 Annotated Model Agreement, supra note 142, at 335.
255 Id. at 330.
256 Micro B3 Brochure, supra note 234, at 3.
257 Caroline von Kries et al., Micro B3 Model Agreement on Access to Marine Microorganisms and
Benefit-Sharing (Dec. 17, 2013),
https://www.microb3.eu/sites/default/files/pdf/MICRO-B3ABSmodel agreement-1 7122013%20expl
anatory%20notes.pdf [hereinafter Kries et al., Model Agreement 2013].
25' WP8 Webpage, supra note 250.
259 Annotated Model Agreement, supra note 142, at 331.
2020]
THE YALE JOURNAL OF INTERNATIONAL LAW
The model agreement is between the original user of the genetic
resources, the 'Recipient', and the Provider State.26 ° It is designed to apply to the
utilization of genetic resources and to cover all potential research outcomes,
including public domain research, commercial research and development, and
situations where the genetic resources are initially used for non-commercial
research purposes but are later used in the production of a commercial product. 26 1
The latter is deemed a "hybrid" situation and is covered by a "change of intent
clause" where the Provider maintains the right to renegotiate benefit sharing
under MAT if the intended utilization of the genetic resource in question
changes. 262 It is worth noting here that this clause "does not give the Provider a
one-sided right to withdraw its consent, but rather enables it to renegotiate the
contract."
263
Another article of note in the Micro B3 model agreement is the inclusion of a
viral license clause, which states that third parties receive the resources under the
same terms as the original Recipient.2' The agreement explains the viral license
clause further:
This clause guarantees that all the obligations of the initial
agreement will be imposed on subsequent use of the materials
and the produced data when transferred. When the viral license
clause is used, the scientist/scientific institution is allowed to
transfer the material to third parties if they sign a new contract
in which they commit themselves to respect the conditions of
the initial ABS agreement ... At each transfer however,
according to the Nagoya Protocol, consent is required from the
competent national authority in the provider country[.]
2 65
3. Implications for Large-Scale Biological Projects:
The Micro B3 project created various tools and standardized agreements that
can be modified and tailored for use with other projects. The "absence of an
overarching legal framework for access and benefit sharing in the marine
environment" was seen as one of the major obstacles "limiting the usability of
the ever increasing datasets for marine biodiversity research and
biotechnological applications." '266 Therefore, creating a workable ABS policy
was one of the primary objectives of the Micro B3 project from the outset, setting
260 The text of the Micro B3 model agreement, as well as an extensive commentary on all of its articles
is provided in Model Agreement 2013, supra note 257. Much of the discussion here is based on that
commentary.
261 Annotated Model Agreement, supra note 142, at 331.
262 Id. at 345.
263 Id.
26 Model Agreement 2013, supra note 257, at 4; see Model Agreement, supra note 142, at 345.
26 Model Agreement 2013, supra note 257, at 4. See Model Agreement, supra note 142, at 345.
266 Final Report Summary - MICRO B3 (Marine Microbial Biodiversity, Bioinformatics and
Biotechnology), CORDIS, https://cordis.europa.eu/project/rcn/101555/reporting/en?rcn=174440 (last
updated June 29, 2016).
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it apart from other large scale research projects where the primary objective was
the collection and analysis of research data.
Since the Nagoya Protocol did not enter into effect until October 12, 2014,
the Micro B3 project got a head start on determining how its provisions were
likely to affect large-scale scientific activities, creating "[a]n innovative legal
framework and model contracts for the protection and sustainable use of marine
genetic resources."267 The resultant model agreement complies with the
requirements of the Nagoya Protocol, recording the granting of PIC268 and
establishing MAT.269 It provides both the Recipient and the Provider of the
marine, microbial genetic resources sourced from the Provider's sovereign
territory with legal certainty about the permissible uses and the terms of benefit
sharing before those samples are even collected. For the purposes of the Micro
B3 project, the model agreement "was hardly used, because the [participating]
coastal States, most of which were European, either did not operate an ABS
regime or did not apply it because the samples were taken by their own research
teams., 270 The attention paid to ABS and the associated issues of IP protections,
along with the outputs generated by the IP Work Package of the Micro B3
project, offer significant insight as to how ABS can and should be approached
by other large-scale scientific endeavors to ensure compliance with ABS
regulations and legal clarity for all stakeholders.
With respect to PIC under Nagoya, the creators of the Micro B3 model
agreement noted that:
"Whether a Provider State has established an ABS regime or
not can only be determined by examining its domestic
legislation and practices. According to upcoming rules of User
States, a due diligence obligation applies in such cases. This
means that the researcher has to take due care to find out the
domestic procedure of the Provider State, if any exists. He/she
is not required to carry out an in-depth legal analysis. Rather, it
is sufficient diligence if he/she seeks advice at the national focal
point on ABS of the Provider State."
271
This statement reinforces the fact that informal transfers of genetic resources,
even for non-commercial research purposes, are no longer appropriate.
Researchers must now exercise due diligence in meeting ABS obligations. 272
26 7Background, MICRO B3, https://www.microb3.eu/about.html (last visited Nov. 13, 2019).
268 See Annotated Model Agreement, supra note 142, at 346.
269 See id. at 33 1("The aim of the Model Agreement is thus to serve as model contractual clauses for
mutually agreed terms according to Article 19 of the Nagoya Protocol.").
270 EVANSON CHEGE KAMAU & GERD WINTER, Unbound R&D and bound benefit sharing, in
RESEARCH AND DEVELOPMENT ON GENETIC RESOURCES: PUBLIC DOMAIN APPROACHES IN
IMPLEMENTING THE NAGOYA PROTOCOL 19 (Evanson Chege Kamau, Gerd Winter & Peter-Tobias Stoll
eds., 2017).
271 Annotated Model Agreement, supra note 142, at 330-331.
272 See Sivaramjani Thambisetty, Due Diligence and ABS Compliance Under EUR 511/2014 3 (London
Sch. of Econ., Law Policy Briefing Paper No. 33, 2019).
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Even if there is no domestic ABS legislation or regulations in the country from
which researchers wish to obtain samples, it is still worth approaching the
provider nation to determine whether they wish to exercise any form of sovereign
rights (legislative, administrative or policy measures) over the genetic resources
of interest, for no other reason than to ensure that there are no unexpected legal
challenges at a later date, including reputational risk from claims of"biopiracy."
If the NFP (or CNA) of the provider nation chooses to waive its sovereign right
to participate in ABS negotiations for the genetic resources of interest, it is worth
getting this decision in writing so as to demonstrate later that sufficient steps
were taken to establish whether ABS obligations existed at the time of access.
One major implication of the Micro B3 project's analysis of ABS
requirements and the development of its Nagoya Protocol-compliant model
agreement is the indirect recognition that any data gleaned from the physical
samples of microbial genetic resources belongs to the same jurisdiction from
which the physical samples originated. Indeed, it has been noted that "the Micro
B3 Agreement is a good example of how benefit sharing obligations can travel
with the digital resource separately from the physical sample."273 The model
agreement details the terms of use not only for the "accessed genetic resource"
but also for "associated genetic knowledge," which is defined as "any
experimental or observational data, information and other findings on the
composition, life conditions and functions of the accessed genetic resources."274
The model agreement contains clauses that ensure that the ABS "obligations of
the initial ABS agreement... will be imposed on any third party receiving the
material and/or the knowledge associated with the [genetic resource]., 275 This
application of viral clauses to the original sample and to the data, information,
and knowledge that are associated with that sample are something that should be
considered when initiating a bioprospecting project, whether or not there is
commercial intent.
The Micro B3 project recognizes that the adoption of "appropriate"
ABS rules can actually "promote R&D activities ... and generate funding for
biodiversity conservation." 276 There are undoubtedly major administrative
hurdles that accompany these sorts of activities; ABS regulations are but one
source of such hurdles. The Micro B3 project's model agreement provides a
workable starting point for those wishing to access microbial genetic resources
for research and development, and it clarifies how some of the more ambiguous
ABS provisions of the CBD and Nagoya Protocol might be settled. The key point
is that ABS, as it is outlined in these international instruments, is a compromise
between the provider and recipient parties. The Micro B3 project's model
agreement establishes a practical compromise that ensures the efficient
production and promulgation of public-domain scientific information while
273 Fran Humphries, Banking on a Patent Solution for Sharing Antarctica's Ex Situ Genetic Resources,
in BIODIVERSiTY, GENETIC RESOURCES AND INTELLECTUAL PROPERTY 62 (Charles Lawson &
Kamalesh Adhikari eds., 2018).
274 Kries et al., Model Agreement 2013, supra note 257, at 8.
275 Annotated Model Agreement, supra note 142, at 347.
276 WP8 webpage, supra note 250.
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guaranteeing that a portion of the benefits from subsequent commercial
applications will be shared with the resource provider. According to Pooja Bhatia
and Archana Chugh, under Micro B3, "agreements in line with the national laws
shall be more effective. The marine bioprospecting contracts can be a significant
tool for the development of a successful access and benefit sharing mechanism
that will safeguard the interests of the indigenous communities as well as monitor
the use of marine bioresources in an environment friendly and sustainable
manner."
277
D. Earth BioGenome Project (EBP)
1. Project Description andAims:
The idea of the Earth BioGenome Project (EBP) evolved out of a meeting at
the Smithsonian Institute in November 2015,278 and the Project was announced
on February 23, 2017.279 The ambitious aim of the EBP is to genetically sequence
the Earth's known eukaryotic species (approximately 1.5 million plant, animal
and fungal species) over ten years. 280 The plan is to fully annotate (describe) the
genetic sequence data and make it available for use by the scientific community
and industry, forming the building blocks of further research, development and
innovation.
In January 2018, a partnership between the EBP and the Earth Bank of Codes
was announced at the World Economic Forum in Davos, Switzerland. 281 The
Earth Bank of Codes will store the genetic sequence data, encoding information
about its origin and terms of use. The collaboration between the EBP and the
Earth Bank of Codes is part of the World Economic Forum's "Fourth Industrial
Revolution for the Earth" initiative and is being sold as an investment
opportunity to leverage funding from public-private partnerships.282 The
endeavor is expected to cost around US$4.7 billion, an outlay that the EBP sees
as something of a bargain given the ability of the US$3 billion Human Genome
Project to contribute "nearly $1 trillion" to the US economy in the first ten years
after its completion.283
277 Pooja Bhatia & Archana Chugh, Role of Marine Bioprospecting Contracts in Developing Access and
Benefit Sharing Mechanism for Marine Traditional Knowledge Holders in the Pharmaceutical Industry,
3 GLOBAL ECOLOGY AND PRESERVATION 176, 187 (2015).
278 Sequencing the World, supra note 170.
279 Elizabeth Pennisi, Biologists Propose to Sequence the DNA ofAll Life on Earth, SCI. MAG. (Feb. 24,
2017), http://www.sciencemag.org/news/2017/02/biologists-propose-sequence-dna-all-life-earth.
28 Roadmap: Project Plan, EARTH BIOGENoME PROJECT, https://www.earthbiogenome.org/roadmap
(last visited Nov. 13, 2019).
281 Lisa Howard, Earth BioGenome Project Aims to Sequence DNA From All Complex Life, U.C. DAVIS
(Apr. 23, 2018), https://www.ucdavis.edu/news/earth-biogenome-project-aims-sequence-dna-all-
complex-life.
282 Fon Mathuros, New Partnership Aims to Sequence Genomes ofAll Life on Earth, Unlock Nature's
Value, Tackle Bio-Piracy andHabitat Loss, WORLD ECON. F. (Jan. 23, 2018),
https://www.weforum.org/press/2018/01/new-partnership-aims-to-sequence-genomes-of-all-life-on-
earth-unlock-nature-s-value-tackle-bio-piracy-and-habitat-loss.
283 Howard, supra note 281.
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Chaired by Professor Harris Lewin of U.C. Davis and co-chaired by John
Kress of the Smithsonian Institution and Gene Robinson of University of
Illinois,284 the leadership team of the EBP comprises interdisciplinary experts
from the United States, United Kingdom, China, Germany, Korea, Australia,
Chile, Canada, Norway, Spain, Denmark, and Brazil.285 The Project is currently
in its infancy but is expected to consist of a "global network of communities"
that will contribute specimens and data to the EBP.286 Sample collection, data
generation, and analysis will begin in the eight countries of the Amazon basin,
287
which hosts 20-25 percent of the world's land-based biodiversity.288 This will
form something of a pilot project for the global rollout of the EBP in later years.
The EBP has partnered with various scientific institutes that will conduct the
sequencing, including BGI (formerly known as the "Beijing Genomics
Institute") in China, the Wellcome Trust's Sanger Institute in the United
Kingdom, and Rockefeller University's Genomic Resource Center in the U.S.
289
The sequence data generated from this first phase of the EBP in the Amazon will
be stored in the Amazon Bank of Codes, itself a test platform to be trialed before
the worldwide expansion of the EBP and the creation of the larger Earth Bank of
Codes.
The EBP has also partnered with the Global Genome Biodiversity Network
(GGBN), "the world's major resource of tissues and DNA from voucher
specimens," and will also be working to coordinate the collation of data from
other projects, "including the Vertebrate Genomes Project, the Global
Invertebrate Genome Alliance, the 10,000 Plant Genomes Project, the 5000
Insect Genomes Project, and others."290 That is, not all the genomic sequence
data will be generated by the EBP itself, but there is a view to store as much data
as possible in the Earth Bank of Codes. This is key to the EBP because the Bank
of Codes is supposed to form a "global public good digital platform" that makes
the genetic resource genomic data visible and usable by third parties, but where
the "fair and equitable sharing of benefits is embedded in the design" of the
platform: 2
9 1
It would support national governments and states in Amazon-
basin countries to implement the Nagoya Protocol ....
Importantly, the platform would represent a broad-based
284 Leadership, EARTH BIOGENOME PROJECT, https://www.earthbiogenome.org/ebp-leadership (last
visited Nov. 13, 2019).2 85 Participating Institutions, EARTH BIOGENOME PROJECT,
https://www.earthbiogenome.org/participating-institutions (last visited Nov. 13, 2019).
286 Howard, supra note 281.
287 World Economic Forum, Juan Carlos Castilla-Rubio: Unlocking the Value of The Amazon,
YOUTUBE (Apr. 26, 2018), https://www.youtube.com/watch?v=QCQr9-3XFKk&feature=youtu.be
(presentation given to the World Economic Forum in Davos, January 2018) [hereinafter Castilla-Rubio
Youtube talk].
288 EARTH BANK OF CODES, https://www.earthbankofcodes.org (last visited Nov. 13, 2019).
289 Sequencing the World, supra note 170.
2"6 Howard, supra note 281; see Pennisi, supra note 279.
291 Castilla-Rubio Youtube talk, supra note 287.
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partnership between the Amazonian nations' biodiversity
regulatory authorities and multistakeholder coalitions. By
unlocking significant economic value from the Amazon basin,
an inclusive bio-based economy is feasible for the first time in
history.29 2
2. Capacity Building and Access and Benefit Sharing
One of the objectives of the collaboration is to create an "inclusive bio-
economy ' 293 that will support environmental conservation in many of the
world's most biodiverse regions and address issues of biopiracy by distributing
a portion of the benefits from the use of genetic sequence data back to the nations
of origin. In this sense, the EBP and Earth Bank of Codes collaboration is not
only supportive of the CBD and Nagoya Protocol-it also intends to use new
computing technologies to influence how ABS is conducted into the future. 2 94
Some of the physical samples for the EBP will be obtained from member
institutes of the GGBN "which is compiling lists and images of specimens at
museums and other biorepositories around the world., 295 This means that
samples will be used in accordance with the GGBN standards and policies. "The
[GGBN] standard requires that genetic samples provided for research by GGBN
member institutions (i.e., nonhuman biological repositories) be associated with
permitting and other legal information associated with access and benefit
sharing." 296 The Smithsonian Institute will also be a valuable source for
eukaryotic samples that can be genetically sequenced. These institutions,
however, only house a small subset of the world's eukaryotic species and so the
EBP will need to branch out and collect samples from nature. The samples would
be obtained from participating partners and, interestingly, the Project "also plans
to capitalize on the 'citizen scientist' movement to collect specimens.,,297
The EBP does plan to make ABS policy documents and agreements
available online, although at the time of writing these "were currently under
development., 298 It is clear from the Project's promotional materials that ABS
issues lie at the very core of the EBP mission. The leadership team has stated
that participants from around the world will have to comply with domestic ABS
laws:
292 Harnessing the Fourth Industrial Revolution for Life on Land, WORLD ECON. F. 18 (2018),
http://www3.weforum.org/docs/WEFHarnessing_4IR Life on Land.pdf.
293 Id. at 15-16.
294 Id. at 16.
295 Pennisi, supra note 279.
296 Harris A. Lewin et al., Earth BioGenome Project, 115 PROC. NAT'L ACAD. SC1. U.S. 4325, 4331
(2018).
297 Howard, supra note 281; see Lewin et al., supra note 296, at 4329.
291 Cooperation Agreement Between FAPESP and the Earth Biogenome Project, SAO PAULO RES.
FOUND. (July 19, 2019), http://www.fapesp.br/en/1 3011.
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The EBP will adhere to the principles of the Nagoya Protocol
by (i) requiring participants to comply with regulations on
biodiversity use at the national level and (ii) using the
established tools and resources on access and benefit sharing.
Specifically, the EBP aims to provide fair, equitable, open, and
rapid access to and sharing of the benefits of the eukaryotic
genomes of planet Earth.2 99
Access to the territory to collect samples from participating countries is,
however, still seen as a political challenge for the EBP to overcome,300 and the
leadership team acknowledges that the project could be delayed by interruptions
to the sample-acquisition pipeline.3 1 While there is substantial discussion about
the regulation of data accessed from the Bank of Codes and how the benefits of
the use of genetic sequence data will be distributed, there is much less discussion
about whether the EBP intends to engage in benefit-sharing negotiations for
access to the physical samples in order to generate the sequence data. This could
be seen as the initial upstream use of the physical genetic resources by the EBP
and its associates. There is little doubt that "[t]he EBP will comply with access
and benefit sharing laws through partnerships with organizations, such as the
Amazon Third Way Initiative and the Amazon Bank of Code." 302 It is just the
case that it is not yet clear precisely how this will be achieved.
Downstream benefit-sharing by third-party users of the genetic
sequence data is integrated into the design of the EBP and its Bank of Codes.
The founder of the Amazon Bank of Codes, Juan Carlos Castilla-Rubio,
30 3
describes the database as "an open library of the Amazon's biological data
(particularly DNA sequences)" which will "also track who does what with those
data, and automatically distribute part of any commercial value that results from
such activities to the country of origin."30 4 This will be achieved using
Blockchain, the technology that "underpins" cryptocurrencies like Bitcoin.3°5
With the introduction of Bitcoin in 2009, Blockchain technology and
Bitcoin were essentially synonymous until the separation of Blockchain, or
distributed ledger technology--distributed databases that maintain continuously
growing lists of ordered records.30 6 Today, this technology is becoming
ubiquitous and is "used for all kinds of interorganizational cooperation."307
Blockchain can be defined as a:
299 Lewin et al., supra note 296, at 4331.
3 0 Ben Schiller, How A Bank OfAll The World's Genetic Codes Hopes To Save Nature, FAST
COMPANY (Feb. 28, 2018), https://www.fastcompany.com/40534363/how-a-bank-of-all-the-worlds-
genetic-codes-hopes-to-save-nature.
31 See Lewin et al., supra note 296, at 4329-30.
302 Lewin et al., supra note 296, at 4333,
303 Mathuros, supra note 282.
31 Sequencing the World, supra note 170.
305 Id.





Distributed electronic ledger that uses cryptographic software
algorithms to record and confirm immutable transactions
and/or assets with reliability and anonymity. It has no central
authority and allows for automated contracts that relate to those
assets and transactions (smart contracts). 30 8
Juan Carlos Castilla-Rubio from the World Economic Forum's Global Future
Council on the Environment and Natural Resource Security 30 9 recognized the
potential for this technology in creating a "bio-economy":
By registering biological and biomimetic intellectual property
(IP) assets on blockchain, this code bank will record the
provenance, rights and obligations associated with nature's
assets to track their provenance and use. When value is created
from accessing these assets, smart contracts would facilitate the
fair sharing of benefits to the custodians of nature and for its
protection. 31
0
Thus, the use of genetic sequence data by third parties that access that data from
the (Amazon or Earth) Bank of Codes is tracked, providing a mechanism for
originating nations to obtain benefits if the use of their data results in a market
product or process. Indeed, the Bank of Codes system "can be employed to create
'smart contracts' that monitor and execute themselves." 311 In order-for such a
system to work, one assumes there would need to be a matrix of contracts: one
set of legal agreements between the originator countries and the Bank of Codes,
another between the Bank of Codes and individual third-party users (probably
terms of use agreed to upon registering as a user of the Bank of Codes), and then
the "smart contracts" that would represent a legal agreement between the third-
party user and the country of origin, mediated by the Bank of Codes. The EBP
has already engaged with governments, regulators, local communities, corporate
organizations, and scientists to establish the attribution and benefit-sharing
principles inherent in this system. 312 Clearly it is more complicated than a
standard bilateral ABS agreement, but the transaction costs absorbed by the
establishment of the Bank of Codes would reduce the barrier to entry for
potential (academic and commercial) users, giving them legal clarity about the
terms of use and negating the need for them to enter into protracted bilateral ABS
negotiations themselves. Reducing such barriers could go a long way to finally
making ABS a financially viable mechanism to capture benefits for the providers
of genetic resources.
3. Implications for Large-Scale Biological Projects
3o8 Harnessing the Fourth Industrial Revolution for Life on Land, supra note 292, at 16.
309 Mathuros, supra note 282.
31" Harnessing the Fourth Industrial Revolutionfor Life on Land, supra note 292, at 16.
311 Sequencing the World, supra note 170.
312 Castilla-Rubio Youtube talk, supra note 287.
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Like the Micro B3 project, the EBP is noteworthy for its embrace of the ABS
objectives of the CBD and Nagoya Protocol. Where the EBP differs is in its
collaboration with the Amazon Bank of Codes, which not only respects ABS
requirements but also intends to track the use of resources and automatically
executes benefit-sharing agreements. This is something the collaboration hopes
to take to the Conference of the Parties to the CBD in 2020, with a view to "help
redraw several components of the CBD itself." 313 The EBP will not only comply
with ABS regulations, it could potentially shape the way ABS is conducted in
the future.314 A report published in the Proceedings of the National Academy of
Sciences concludes that "the economic impact of the EBP is likely to be very
large and globally distributed.
315
Past biological research projects often treated ABS regulations as an
afterthought, an obstacle that has to be overcome in order to conduct the
important work of the project. The EBP is significant, as it has ABS at the very
core of what it wants to achieve: "A goal of the EBP is to globalize its activities
through novel partnerships that build scientific capacity in developing countries,
including the capacity to utilize, not just create, a legacy resource."'316
The implementation of technology may make some of the aspirational goals
of the CBD and Nagoya Protocol more practical. The World Economic Forum
rightly noted that the "[h]uman capacity to capture, store and process data has
been transformed to a degree impossible to conceive at the time of the Rio
Summit. '"317 While the operational details are still unclear, technologies like
Blockchain hold real potential to transform the ABS landscape, making what has
been a very flawed concept more workable. In particular, it has the potential to
deal with some of the issues surrounding the use of the intangible aspects of
genetic resources that includes data, information, and traditional knowledge.
Regulating the transboundary movement of physical biological samples has
proven exceptionally difficult and inefficient, and there are additional problems
associated with the movement and use of data and information. Without a radical
redesign of the default bilateral transactional ABS model that has thus far proven
ineffective as a wealth redistribution device and as an environmental
conservation mechanism, the international community may have to rely on
technological solutions to the ABS problem.
One of the main ABS problems that the Bank of Codes could solve is
determining what is considered non-commercial versus commercial utilization
of genetic resources. Quite often it is unfeasible to determine whether the use of
a genetic resource (or in this case, its sequence data) will result in a commercial
product. By tracing the inputs to research and development (or at the very least,
monitoring the users who are likely to create commercial outputs), there is a
313 Harnessing the Fourth Industrial Revolution for Life on Land, supra note 292, at 16.
314 There is great potential for these technologies to assist with ABS, but they are unlikely to resolve
some of the more conceptual or political issues of ABS.
315 Lewin et al., supra note 296, at 4332.
316 Id. at 4329.
317 Harnessing the Fourth Industrial Revolution for Life on Land, supra note 292, at 11.
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greater likelihood of detecting when monetary benefits are generated and ought
to be distributed to provider nations. The World Intellectual Property
Organization (WIPO) has been considering mandatory disclosure of the country
of origin on patent applications that could also address this problem since the
early 2000s. 318 The country of origin disclosure on patent applications would
have the added benefit of capturing the use of physical genetic resources and any
sequence data that happened to be accessed outside the proposed Bank of Codes.
However, the advantage offered by technological solutions like the Bank of
Codes is that the system does not rely on the honesty of patent applicants at the
downstream end of the innovation process. Rather, users are registered at the
upstream stages where there are not yet as many vested interests in maximizing
far-off profits.
This is not to say that regulatory technologies hold all of the answers.
There are still major problems associated with ABS that cannot be fixed by
Blockchain and similar ledger technologies. The Blockchain approach does not
yet track the use of physical samples of genetic resources. There are undoubtedly
ways to integrate this Bank of Codes approach to include physical biobanks,
however, the Bank of Codes is still just a concept: it has not yet been created or
tested. There are many ways to share data outside of the Bank of Codes system;
digital sequence information which is represented as just a string of characters
('A', 'G', 'C' and 'T's), can easily be emailed to people who have not registered
with the Bank of Codes. There is also the issue of convergent and divergent
evolution: many genes have similar structures across different species, so if there
is a sequence of interest in the Bank of Codes, there is very likely a similar one
available elsewhere (published on the openly accessible GenBank database, for
instance) that is not associated with terms of use.
The objective of fair and equitable benefit sharing within the CBD and
Nagoya Protocol were a response to the exploitative research and development
practices of technologically advanced countries utilizing the genetic resources of
biodiverse low- and middle-income countries. As a result, large-scale
biogenomic projects are, to a large extent, starting to incorporate these equity
imperatives in the design of their projects. This is not to say that the problems
that the CBD and Nagoya Protocol sought to address have been resolved, that
the mechanism of choice - access and benefit sharing - has been entirely
successful, nor that the power imbalances that were once pervasive in
international scientific collaborations have disappeared completely. However, it
does demonstrate that these large-scale international projects and the scientists
at their helm recognize the requirement and inherent value of sharing the benefits
of scientific research and development with countries of origin and helping to
build capacity for future scientific efforts in those nations.
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IV. CONCLUSION
International research collaborations in the life sciences have unlocked
critical innovations toward the benefit of human health and welfare. The rapid
proliferation of genetic sequencing technologies, big-data analytics, and
awareness of the wealth located in the earth's biodiversity are opening
significant, global opportunities for these innovations to be realized ever more
quickly with even greater impact on humanity. Contemporaneously with these
movements in technology, national and international law have moved to ensure
that past disparities in the exploitation of natural resources are not repeated and
that the basic human needs of the earth's population are fairly addressed.
These are all issues for which the fixes may also be technological, but there
are also the more vexing justice issues of ABS that have been in question for
decades. For instance, who decides what is "fair and equitable" when it comes
to attribution and benefit-sharing? How do users ensure that indigenous peoples
and local communities are receiving a fair share of the benefits when ABS is
negotiated with the governments of States Parties and not the indigenous
communities themselves? How is the share of benefits attributed if there are
multiple jurisdictions in which a gene of interest naturally occurs? These are
questions of value that regulatory technologies cannot address. They will require
good old-fashioned diplomacy and slow-going compromise through
international forums. Twenty-five years after the introduction of the CBD, we
are still grappling with many of the same issues of equity and justice that the
CBD was an attempt to address.
This Article has endeavored to analyze how international law is shaping
these currents and how notions of fairness have emerged to shape where
investments in research should be ethically made. The analysis of global
biogenomic enterprises herein has focused on how genetic resources are
collected and studied, and how projects may proceed through the changing legal
landscape of ABS. The early evidence is that these projects not only integrate
the transfer of knowledge and technology as an inherent objective, but also have
made explicit plans for the sharing of benefits arising from the utilization of
genetic resources.
[Vol. 45: 1
